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ABSTRACT
It is an FDA requirement that the “first in human” dose be based on pre-clinical
animal model efficacy and safety testing to ensure a safe entry into Phase I clinical trials.
Pre-clinical safety and efficacy models range from mouse to non-human primates.
Interspecies scaling of pharmacokinetic parameters is therefore important for predicting
drug doses in human clinical trials, although it continues to be less than optimal.
Understanding the disposition of the compound in different species through in vitro and
in vivo experiments is necessary to ensure appropriate species are selected for human
estimates. Data for three imaging agents and a pharmacological stress agent (Oncology
tumor agent (DPC-A80351), Thrombus agent (DMP-444), Infection agent (RP-517)
Pharmacological stress agent (DPC-A78445-00)) that entered clinical trials and an
imaging agent being developed (RP845), were assessed for scaling accuracy.  Initially,
pharmacokinetic data from animal models were used to extrapolate to human though
body weight allometric scaling.  Subsequently, the impact of adjusting for plasma protein
binding and the impact of metabolic stability in the different models were examined.
Allometric scaling of animal pharmacokinetic parameters (clearance (CL), half-
life (t½) and volume of distribution (Vdss)) achieved a prediction of the human
pharmacokinetic parameter within 13 to 109% of the observed values.  This prediction
was further improved by adjusting for plasma protein binding of the drug, and achieved
an estimate within 5 to 57% of the clinically observed values. Since the parent compound
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was the dominant species (>95%) in the circulation, metabolic stability was not used as a
correction factor.
Weight based allometric scaling was further examined for an atherosclerotic
plaque targeted radiopharmaceutical imaging agent, RP845-Tc-99m, currently in
development. Pharmacokinetic parameters were determined in mouse, rat and rabbit
followed by allometric scaling to predict the non-human primate values.  Differences
between predicted versus observed non-human primate Cl, t½ and Vdss were 40%, 52%
and 8%, respectively.  Correcting for plasma protein binding improved the prediction for
Cl and t½ to within 12 and 3 %, respectively. The Vdss prediction, however became less
accurate (38% difference).  Since blood clearance is the major parameter in predicting
human dose, the improvement from 40% to 12% was important. The plasma protein
binding adjusted animal data was then used with allometric scaling to predict human CL,
t½ and Vdss.  The predicted values were 7.6 mL/min/kg, 70.6 minutes and 0.87 L/kg
respectively. Based on the predicted human blood clearance and the dose required to
image atherosclerosis in a rabbit model, the estimated human dose would be
unacceptably high.  This demonstrates how allometric scaling can be used in research
projects to assess clinical feasibility.
The impact of metabolism differences influencing the reliability of various
species to predict for man was highlighted by DPC-A78445-00. DPC-A78445-00 is being
developed as an alternative to exercise in myocardial perfusion imaging for the
evaluation of coronary artery disease. DPC-A78445-00 was rapidly metabolized to the
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carboxylic acid by mouse and rat blood in vitro and in vivo, however longer stability was
observed in the dog. In vitro human blood data was consistent with the dog, suggesting
that mouse and rat would not be representative species. DPC-A78445-00 plasma protein
binding was at a similar, moderate level in rat, dog and human plasma and metabolism by
hepatocytes was similar in dog and human.  Phase I human clinical trial testing
determined the area under the blood concentration-time curve (AUC) and clearance
predicted by the dog were within 32% of the human values.
Overall, body weight based allometric scaling of pharmacokinetic parameters
from animal models, when corrected for plasma protein binding, yielded reliable
predictions of the human pharmacokinetics (within 50%) for radiopharmaceutical
imaging agent. However, although predictive scaling from animal data can give insight
into feasibility of compounds working in human, it is important to identify species
differences with respect to metabolic stability. This allometric scaling method provides
an additional tool to better predict doses in human for novel Medical Imaging agents.
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1. CHAPTER I
1.1 Background and general overview
1.1.1 Overview statement
Predicting the pharmacokinetics of radiopharmaceutical imaging agents in
humans from pre-clinical animal models with high accuracy would result in a safer more
efficacious selection of first dose in clinical trials.  Fewer dose ranging studies, subjects,
and clinical trials would be necessary and could result in a shorter time for introducing a
drug that meets an unmet medical need.  Translating how the body distributes and clears
the drug in animals into a best estimate of the human condition is difficult.  For
therapeutic agents, dose prediction has been attempted with various scaling methods and
a wide range/number of animal models, various drug characteristics/dispositions and
different routes of drug administration. The predicted effective dose for new imaging
agents entering Phase I studies at Bristol-Myers Squibb Medical Imaging (BMS-MI) has
often been based on the non-human primate or a species seen to be representative of the
human based on in vitro testing  (i.e. hepatocyte assays).  Human dose prediction from
the “relevant” species has typically been based on a body weight extrapolation and has
not utilized all the data available.  The research project described below examines the use
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of allometric scaling to better utilize the information from all the animal models to
predict the safe and efficacious clinical dose for medical imaging agents.
1.1.2 Pharmacokinetics
Pharmacokinetics is the study of what the body does to a drug as opposed to
pharmacodynamics, which is what the drug does to the body.  To better define
pharmacokinetics, the acronym “ADME” is used which stands for absorption,
distribution, metabolism and excretion.  Absorption is the process by which a compound
and its metabolites are transferred from the site of application (intravenous (IV),
intramuscular (IM), subcutaneous (SubQ), oral, inhalation, topical) to the systemic
circulation.  In the case of radiopharmaceutical medical imaging agents, the drug is
typically administered intravenously and therefore has 100% absorption.   Distribution is
where the drug locates following absorption.  This is determined by measuring the
concentration of drug in tissues and organs either by collecting samples (biodistribution)
or imaging.  Metabolism is the conversion of the parent agent to metabolites.  These are
detected and identified by sampling tissues, plasma, urine, bile, and feces.  Blood and
liver (cytochrom P450) are the two main organs of the body that metabolize drugs, with
other tissues in the body (kidney, lung) also capable of metabolic activity to a lesser
degree. Excretion is the route and rate of elimination of the agent from the body.  This is
typically determined through tissue distribution and mass balance studies.  The two major
clearance routes for most agents are renal or hepato-biliary.
19
1.1.3 Pharmacokinetic parameters
Pharmacokinetic parameters that have been used for scaling from pre-clinical animal
models to humans are A) blood clearance (CL), B) terminal half-life (t1/2) and C)
volume of distribution at steady state (Vdss).  These are defined below:
A) Blood clearance is the rate an organ system totally extracts a drug from
plasma.  The units for clearance are mL plasma/minute/kg body weight and is calculated
as:  CL = Dose/Area under the blood concentration-time activity curve (AUC).
B) The terminal half-life of a drug is the time required for the plasma
concentration to decrease by 50% after absorption and distribution are complete.
Terminal half-life is expressed in time (min, hr) and is calculated as:  T1/2= 0.693/slope
of the blood concentration-time curve.
C) Volume of distribution describes the extent of distribution of a drug and is
useful in determining the size of the dose required to reach the desired blood
concentration of the drug. The units are expressed in L/kg and is calculated as:  Vdss =
(Dose x AUMC)/ (AUCinf X AUCinf) (AUMC=area under the moment curve, AUCinf=
area under the curve from time zero to infinity).  Volume of distribution of the central
compartment can play an important role in establishing the safety or toxicity for first dose
in humans. Since the administered dose is known, the predicted Vdss can be used to
calculate the plasma concentration of a drug at time zero following an intravenous
injection.
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These three parameters provide information for determining total exposure of a
drug to the target and non-target organs with a given dose. They are therefore appropriate
parameters to use when scaling the potential efficacy or toxicity from species to species
1.1.4 Radiopharmaceuticals
Radiopharmaceuticals play an integral role in clinical nuclear medicine by
providing a tool to better understand human disease and develop effective treatments.
Nuclear medicine continues to grow with the commercial availability of new
radioisotopes and the discovery of novel radiopharmaceuticals. The properties of a
radioisotope such as the half-life (decay time to reach half the starting radioactivity) and
the type of radiation emitted (i.e. gamma, beta, positron) are important selection criteria
for either diagnostic or therapeutic use.  The path length or distance traveled by the
radiation is an important consideration in selecting the isotope. For instance, in the case
of a diagnostic imaging agent, high penetrating gamma rays would be preferred with
isotopes such as technetium-99m, inidum-111, thallium-201, gallium-67 and iodine-123
to effectively penetrate through the body for detection with a gamma camera. In contrast,
if a radiopharmaceutical is delivered in close proximity to a tumor for therapeutic
applications, the isotope would have a short path length and high energy such as iodine-
131, strontium-89, renium-186, yttrium-90 and phosphorus-32.  The radiohalogens, for
example, were responsible for some of the early growth in nuclear medicine with iodine
isotopes, such as 131I, 123I and 124I for diagnosis and therapy (ie imaging and treatment of
thyroid diseases).  The use of short lived single photon emitted computed tomography
21
(SPECT) isotopes, such as 201TI, 111In and 67Ga, are continuing to grow for diagnostic
imaging of the heart, tumors and sites of inflamation/infection.
A radiopharmaceutical is typically comprised of three components: a targeted
ligand, a linker/spacer with pharmacokinetic modifying properties (PKM) and the
chelator for carrying the radionuclide (Figure 1.1).  Each of the components can vary in
size (molecular weight) depending on the unique isotope being chelated to the molecule,
the length of the spacer required for the desired pharmacokinetic profile and the targeting
ligand. The ligand is designed to have high affinity for a selected receptor and is either an
agonist or antagonist, which has no pharmacological effect at levels administered
(Silverman, R.B., 1992).  The linker portion of the molecule can act as a spacer to
potentially alleviate steric hinderance of the receptor/ligand binding interaction or as a
pharmacokinetic modifier, which plays a role in changing the disposition of the molecule
in the body with respect to blood clearance, binding to target/background tissues and/or
route of clearance (Crum-Brown and Fraser, 1868 ; Silverman, R.B., 1992).
Figure 1.1 Radiopharmaceutical components
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Radiopharmaceutical diagnostic imaging agents are typically dose limited by the
radioactivity administered as opposed to the absolute amount of active ligand, which
typically limits a therapeutic agent. This is due to the high specific activity of the
radiopharmaceutical, which means that the mass of the active ligand is small relative to
the radioisotope.  A maximum for the radioactivity dose would be reached before
observing a physiological effect from the trace amount of ligand. In most cases, an ideal
radiopharmaceutical imaging agent targets with high affinity, clears the blood rapidly, has
low plasma protein binding, is stable in the circulation and is excreted predominantly
through the kidneys.  These criteria are required to achieve the highest target to
background binding of the compound to allow clear visualization of the intended target
with the selected imaging modality.  Radiopharmaceutical imaging agents, as opposed to
therapeutic agents, vary in the required amount of active drug administered to achieve the
desired result.  Imaging agent drugs are administered in the µg/kg range whereas
therapeutics are administered in the mg/kg range (Focan et. al., 2005; DeNardo et. al.,
2003).  These low doses typically will not saturate enzyme, receptor or clearance
mechanism and therefore make pharmacokinetics easier to interpret.
1.1.5 Interspecies scaling
“Overall, though interspecies scaling of pharmacokinetics requires refinement and
better understanding, the approach has a lot of potential during the drug development
process” (Mahmood et al, 1999). Mahmood, whose work at the Food and Drug
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Administration (FDA) has established him as a leader in the field of interspecies scaling,
captures the scientific value of utilizing scaling techniques for increased success and
speed of providing drugs for unmet medical needs.  Many interspecies scaling methods
have been used, including: MLP (Maximum life-span potential), brain weight, BSA
(Body Surface Area), physiological-based models and allometric scaling as ways to better
predict the fate of drugs administered to humans using pre-clinical data. Varying degrees
of success have been achieved among these techniques when applied to different drug
types over the past several years. However, there still remains controversy among
investigators as to the best prediction methods and the value of using body weight or
body surface area.  Early studies by Dreyer and Ray (1910) indicated that the ratio of
blood volume to body surface area was constant in rabbits, guinea pigs and mice but
decreased with increasing body weight. Baker et al. (1957) also reported that body
surface area is predictive for total blood volume in normal adults, but not across species.
These studies, as well as others, suggest that the use of body surface area to correct
between different species may work well within a small size range for some parameters,
however, may not be linear across the board for all species and physiological parameters.
Pinkel (1958) however, was able to correlate body surface area directly to the total
number of glomeruli and to the kidney weight of different mammalian species (rat, dog,
and human).  Overall, body surface area has proven difficult to use as a tool for
pharmacokinetic predictivity.
Lombardo and colleagues in 2002 proposed the use of physiochemical parameters
of the drug such as logD and pKa values to predict volume of distribution in humans.
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They reported accuracy within 2-3 fold of the observed value and concluded that the
advantage of optimizing this approach would reduce the use of animals for
pharmacokinetic studies.
Two approaches of interspecies scaling have been reported extensively in the
literature over the past decade.  These approaches include physiological based
pharmacokinetic models (PBPK) and allometric methods.  Both methods have
advantages and disadvantages and vary significantly in their ability to predict interspecies
scaling depending on the therapeutic drug, route of administration and mechanism/mode
of action.  PBPK models employ mechanistic based evaluation of drug disposition and
are mathematically complex, time consuming models.  Allometric scaling employs the
hypothesis that body weight scaling of pharmacokinetic parameters is possible for
predicting interspecies doses of a therapeutic drug.  It is, however, currently unclear
whether allometric scaling will provide a good prediction for medical imaging agents that
are generally intravenously administered and often have a higher molecular weight than
therapeutic agents.
1.1.6 Allometric Scaling
Allometric scaling is an interspecies scaling method that employs log
transformation of body weight and pharmacokinetic parameters to extrapolate from
animal models to humans.
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The following equation defines allometric scaling;
Y = aWb
Y = physiological parameter (CL, t½, Vdss)
a = allometric coefficient
W = body weight
b = allometric exponent
The equation can also be expressed as:
Y = log a + b log W
(a = y intercept, b = slope)
Many physical and physiological parameters have been shown to correlate with
body weight in animals as well as humans ( Boxenbaum et al., 1982;  Bonati et al., 1984;
Dedrick et al., 1970; Mordenti, 1986). Weiss and co-workers (1977) assumed on this
basis that pharmacokinetic parameters would also correlate with body weight and
evaluated the extent to which clearance rates and biological half-lives are related to body
weight. They used a simple allometric equation and made certain assumptions that drug
metabolism occurs only in the liver and that liver clearance is contingent on hepatic blood
flow. They found scaling correlates body weight to blood flow using body weight to the
0.75 power. This works in the ideal situation, however metabolism is frequently unrelated
or not limited by hepatic blood flow, which adds complexity to the prediction.  Weiss
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concluded, “Since the exponents of the allometric equations (for blood flow, enzyme
activities, and renal excretion parameters) as well as experimental values have an
exponent near 0.7 (i.e. body weight to the 0.7 power), it is possible (even if the
elimination mechanism is not known) to describe, in many cases, the approximate
correlation’s between and within species.”  Other investigators have also suggested for
many years that the basal metabolic rate scales as the 2/3 or ¾ power of the body mass
and may be used to predict pharmacokinetics (Schmidt, 1983; Calder, 1984; West et al.,
1997; West et al., 1999; Kleiber, 1932; Heusner, 1982; Feldman et al., 1983; Banavar et
al., 1999; Dodds et al., 2001). This example of the body weight rule (ie. rule of
exponents) is a useful tool for investigators to obtain a general guideline for making
reasonable interspecies predictions, however improvements to this method would be
necessary to obtain qualitative, accurate extrapolations.
In addition to differential metabolism affecting interspecies variation, species
differences in absorption, plasma protein binding, biliary excretion, glomerular filtration
and intestinal fluora also play key roles in interspecies predictions.  Recently,
investigators (Nagilla et al., 2004) reported a method of allometric scaling using various
correction factors including: brain weight, maximum life-span potential and glomerular
filtration. Results of their studies indicated a predictive success rate between 18 to 53%
with no increase in accuracy using the correction factors.  They concluded that allometric
scaling with or without their correction factors was sub-optimal in predicting human
clearance based on in vivo pre-clinical data.
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Caldwell and co-workers (2004) presented the possibility of predicting human
clearance, volume of distribution and terminal half-life through allometric scaling of in
vivo rat data alone. They concluded that dividing rat clearance, volume of distribution
and terminal half-life by 40, 200 and 4, respectively, a reasonable qualitative estimate
would allow for go/no-go human pharmacokinetic decisions for drug discovery
candidates.  This approach may be useful for preliminary estimates of toxicology doses.
1.1.7 Selection of Species
The number of species used for prediction and ensuring a range of body weights
among the species tested are important factors to consider when applying allometric
scaling.  If body weights have less than a 5-10 fold range, the slope of the extrapolated
line is not well defined and can easily skew the determined human value.  Having a
varied range of body weights better defines the slope for extrapolation to a 70 kg human
(Figure 1.2). If a species with a body weight greater than 2-3 kg was used instead of the
mouse model (0.025 kg) in this example, the body weights of the three species used for
extrapolation would be close together and potentially skew the extrapolated human
estimate.
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Figure 1.2 Example of blood clearance extrapolation from animal models to human.
Mahmood and co-workers (1996) investigated the efficiency of using two versus
three species for prediction of clearance and volume of distribution of drugs in humans
using allometric scaling.  Their findings suggest that three species are needed for
prediction of clearance, however volume of distribution is predicted equally well using
data from two or three species.  The Drugs examined in Mahmood’s study had either
renal or hepatobiliary clearance and varied between 15- 80% protein binding.  No
corrections were made to the results based on clearance route or protein binding which
may explain the 1- 373 % error between observed and predicted values. Often it is
presumed that the more species used in the prediction model the more reliable the result
(Mahmood et al., 1996).  Although this may be true in some cases, each additional
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species tested requires time, resources and additional animals. The degree of
improvement to the final prediction would need to be evaluated.
1.1.8 Plasma Protein Binding
Plasma protein binding is the amount of drug bound to plasma proteins in the
circulating blood that is typically determined through ultrafiltration centrifugation or
membrane dialysis techniques.  Plasma protein binding plays a critical role in
determining the distribution and clearance of a drug from the blood circulation.  Some
drugs have limited association with the constituents of blood when administered while
others associate or bind to albumin, globulins, lipoproteins and erythrocytes.  Albumin
(~68,000 MW) is the major drug binding protein in plasma comprising 50-60% of the
total protein (Goldstein, 1949; Meyer and Guttman, 1968; Koch-Weser and Sellers,
1976).  Only drugs that are unbound or free in circulation are capable of diffusing
through vessel walls to reach the site of action or be excreted.  The plasma protein bound
drug is maintained in the circulation longer and is released as the free drug concentration
decreases. Free drug is then available for metabolism, excretion or distribution outside
the vasculature.  Blood concentration-time plots usually show a slower clearance profile
over time with increasing plasma protein binding.  If a drug is highly protein bound, the
intensity of its effect may be diminished, however the duration of exposure will be
longer, possibly resulting in an extended effect on the target.  In the majority of cases,
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protein binding is a reversible process that maintains equilibrium in the blood over time
(Calabrese E.J., 1946).
According to Koch-Weser and Sellers (1976), albumin carries a net negative
charge at a physiological pH of 7.3, but is capable of interacting with both positive and
negative charges on drugs. The different binding interactions include electrostatic,
hydrogen bonds, hydrophobic bonds and dipole bonding. Typically, more highly bound
drugs have a lower solubility in water and hydrophobic binding to albumin can be
significant (Calabrese, E.J., 1946). This is true with increasing carbon chain lengths
having an affect on higher protein binding.  In general, Goldstein (1949) concluded that
affinity is increased for large molecules, particularly those containing aromatic rings,
which can contribute to van der Waals forces to the bond energy.  Carbon chain length,
amino acids, aromatic rings, radioisotope chelators and linkers are among the
modifications used in imaging programs to maximize the targeting potential of the drug.
An important consideration in optimizing the SAR of an imaging agent is ensuring the
drug’s characteristics are also optimized relative to visualization of the diagnostic target.
Maintaining low protein binding, which in turn clears the drug from the general
circulation and non-target background tissues faster, will help achieve this goal. In
contrast, therapeutic drugs often require a long duration of action that can be achieved by
increasing plasma protein binding, which in turn increases circulating half-life of the
drug.  Plasma protein binding plays an important role in correcting for allometric scaling
predictions only if there are significant differences in the amount of drug bound between
the species used for modeling.  “When protein binding is low, it will not exert a major
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influence on allometric scaling, however if high or varies between species, it may be
appropriate to scale unbound drug” (Mordenti et al., 1985)
Witiak and Whitehouse (1969) generally observed that human serum albumin
typically bound higher levels of drug than albumin of other species. They found that
human serum bound more drug than rat serum 13 times of 22; 16 of 22 times when
compared to dog serum; 10 of 16 when compared to rabbit serum and 7 of 10 when
compared to mouse serum.  However, in monkey serum this pattern was not observed
with only 7 out of 14 times that human serum bound more drug.  These differences may
be explained by the varying amounts of albumin per species or simply by structural
differences in the albumin from different species.  Plasma protein binding is clearly a
multi-faceted phenomenon that is vastly complex and requires further investigation.
1.1.9 Metabolic stability
The metabolic stability of a drug can vary among species and influence the
pharmacological effects of the drug, toxicity of the drug and route/ rate of clearance from
the body.  Understanding the types of metabolic processes the drug undergoes in vivo is
important when trying to interpret pharmacokinetic results.  Briefly, drug metabolism is
classified in two phases.  Phase I are oxidation, reduction and hydrolyses reactions which
can form products that proceed to Phase II reactions. Phase II reactions are conjugations
(i.e. glucuronidation, glutathione addition) that ultimately make the drug metabolites
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more polar expediting renal excretion and lowering the chance of toxicity.  Williams
(1967) points out that interspecies drug metabolism must focus on the qualitative and
quantitative differences in the activity and specificity of the enzymes catalyzing both
Phase I and II reactions.  Interspecies differences in metabolism may result from
differences in a) the absolute amount of an enzyme, b) the amount of a natural inhibitor
of the enzyme, c) the activity of an enzyme reversing the reaction, and d) the extent of
competing reactions using the same substrate.  Drugs metabolized by both Phase I and II
reactions may be excreted as 1) the original substance, 2) products of the Phase I
reaction, and 3) conjugation products (Williams, 1967).  The proportion of each excreted
will vary significantly between species.  Caution should be exercised when interpreting
interspecies differences in metabolism without considering other important variables,
such as: age, diet, sex, stress, route of administration, size of dose, diurnal variation,
season of the year and daily temperature (Calabrese, E.J., 1946).  Blood stability of a
radioactive compound is typically measured after extraction of the drug from the blood
following protein precipitation, by high-pressure liquid chromatography (HPLC).  All
radioactive entities are separated, counted and individually integrated to determine the
percent of intact parent drug in the sample.  The radioactive counts represent the total
activity in the blood sample, however they do not provide information on the chemical
nature of the species being detected.  The total counts could be a mixture of intact parent
drug, metabolites and unbound radioactive isotope.  If the metabolic profile of the
compound is unknown and the compound is not completely intact, the drug could appear
to be clearing faster or slower from blood because the assay is measuring a metabolite
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clearing and not the parent compound.  These are important factors to consider when
interpreting pharmacokinetic results.
1.1.10 Synopsis
This dissertation research has been focused on the issue of predicting
pharmacokinetics from pre-clinical animal models to humans and ultimately selecting an
efficacious dose for clinical trials. An efficacious dose in humans is based on achieving
the same blood exposure as observed in the animal models that had effective drug
accumulation at the target. Pharmacokinetic differences between species with respect to
how the body handles a drug have been reviewed from the literature.  There are clear
differences within and between species that makes prediction of pharmacokinetics
extremely difficult, although investigators have described various methods to attempt
inter-species scaling. The methods currently used for prediction include physiological-
based models, allometric methods and body surface area (BSA) calculations, however
there is still variability and poor correlation between species depending on the drug class.
Medical imaging agents are typically intravenously administered, small, hydrophilic
compounds that are rapidly excreted from the body via the kidneys. These compounds are
ideally not metabolized, however may have a range of serum protein binding as a percent
of total circulating drug that would alter clearance from the blood and potentially limit
availability to the target.
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 The research outlined below examines the use of the allometric method of
scaling, including correction factors, between species from recent projects at BMS
Medical Imaging.   This has extended previous work describing the usefulness of this
method for therapeutic molecules in medical imaging tracers. The ability to predict the
pharmacokinetics of a drug from pre-clinical animal models for clinical trials in humans
would provide a major enhancement to the compound selection and the safe progression
of drugs into clinical development.
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2. CHAPTER 2
2.1 Hypothesis and Objectives
2.1.1 Research Hypothesis
Efficacious and safe doses of Radiopharmaceuticals / Imaging agents in humans
may be predicted from pre-clinical animal models through allometric scaling and
“correction factors” associated with the pharmacokinetic fate of the drug.  These
correction factors may include adjusting predictive values based on extent of plasma
protein binding and metabolic stability of the drug.
The goal is to produce a mathematical formula that predicts human
pharmacokinetics (less than 30% difference between predicted and observed values) from
administration of the radiopharmaceutical imaging agent in animal models. This model
may provide a more accurate prediction of drug pharmacokinetics in humans based on
interspecies scaling of pre-clinical models providing a more robust estimation of an
efficacious first dose in human.
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2.1.2 Experimental Objectives
The specific and technical objectives of this project are to:
· Apply allometric scaling to pre-clinical and clinical data from recent Medical
Imaging programs to assess how well human pharmacokinetics was predicted.
· Adjust the allometric scaling model for differences in plasma protein binding and
metabolic stability for each of the compounds. Re-evaluate the predicted versus
observed results.
· Test a novel Tc-99m labeled plaque-targeting imaging compound in mouse, rat,
rabbit and primate.
· Apply the allometric method of scaling with correction factors between species for
the plaque targeting imaging agent and predict pharmacokinetics in primate. Evaluate
prediction, then use all species to predict human pharmacokinetics.
· Evaluate an A2a coronary vasodilator in pre-clinical models through in vitro testing
and assess the role of each model in allometric scaling
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3. CHAPTER 3
Prediction of Human Pharamacokinetics for Radiopharmaceutical Imaging Agents
from Animal Models using Allometric Scaling
3.1 Summary
Allometric scaling with and without correction for plasma protein binding was
applied to animal model pharmacokinetic data for three radiopharmaceutical agents taken
into Phase I clinical testing by BMS Medical Imaging.  This scaling was used to predict
human pharmacokinetics and compared to values measured in clinical studies.  Data from
three medical imaging programs, Oncology tumor agent (DPC-A80351), Thrombus agent
(DMP-444) and Infection agent (RP-517) were assessed for their predictive accuracy of
allometric scaling from pre-clinical models to human.  The animal models varied for the
Oncology (mouse, dog, and non-human primate), Thrombus (rabbit, dog, and non-human
primate) and Infection (guinea pig, rabbit, and non-human primate) programs.
Blood clearance (CL), terminal half-life (t½) and volume of distribution (Vdss)
were determined for each animal model and plotted through allometric scaling without
correction factors to predict human pharmacokinetics. Allometric scaling of animal
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pharmacokinetic parameters achieved a prediction of the human pharmacokinetic
parameter within 13 to 109% of the observed values.  This prediction was further
improved by adjusting for plasma protein binding of the drug, and achieved an estimate
within 5 to 57% of the clinically observed values. Since the parent compound was the
dominant species (>95%) in the circulation for all three agents, metabolic stability was
not used as a correction factor.  Based on the human dose calculated from allometric
scaling that would be required to achieve the same drug exposure that provided
scintigraphic images in the animal models, the amount of drug administered in the
clinical trials should have been, and was, sufficient for imaging.
In conclusion, the allometric scaling method corrected for plasma protein binding
yielded a mathematical formula that in most cases reasonably predicted human
pharmacokinetics from administration of the radiopharmaceutical imaging agent in a
minimum of three animal models.  This method will provide an additional tool to better
predict the first efficacious and safe dose in human for novel Medical Imaging
radiopharmaceuticals.
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3.2 Introduction
The following sections provide a brief background on the three BMS Medical
Imaging drugs evaluated for allometric scaling prediction in this chapter. Understanding
the disease target and mechanism of action of each compound is important when
evaluating the pharmacokinetics of the drug and interpreting the results.
3.2.1 DPC-A80351
111In - DPC-A80351 is a selective ligand that binds to the avß3 receptor.   The
avß3 integrin adhesion receptor is present on angiogenic blood vessels in tissues and
tumors (Brooks et al., 1994).  It interacts with a wide variety of extracellular matrix
components and allows vascular cells to invade tissues and form capillary blood vessels
(Varner et al., 1995; Brooks et al., 1996).    An elevated level of expression of the
integrin avß3 on tumor-associated versus normal blood vessels makes this an attractive
target to image tumors.
40
3.2.2 DMP-444
Tc-99m - DMP-444 binds to the glycoprotein IIb/IIIa receptor on activated
platelets with high affinity and specificity (Barrett et al., 1996).  Activated platelets play
an integral role in platelet aggregation and thrombus formation (Plow et al., 1987). Deep
vein thrombosis is the result of a hypercoagulable state coupled with a period of stasis
occurring in a low sheer environment. The end result is the formation of a fibrin rich
thrombus that also contains some platelets and erythrocytes.  In contrast, an arterial
thrombus is the result of the rupture of an atherosclerotic plaque occurring under high
sheer conditions resulting in the formation of a platelet rich thrombus.  Venous and
arterial thrombus formation are common and potentially life-threatening events.  The
binding of DMP-444 to activated platelets provides the opportunity to image this
thrombus.
3.2.3 RP-517
Tc-99m - RP-517, is a ligand for the LTB-4 receptor found on activated
neutrophils (van Eerd et al., 2003; Tager et al., 2003).  Activated neutrophils are found at
sites of inflammation occurring in response to tissue damage.  This tissue damage can
result from microbial invasion, auto-immune processes, neoplasms, ischemia, tissue or
organ allograft rejection, or such external influences such as heat, cold, radiant energy,
chemical stimuli or mechanical trauma.  Imaging of RP-517 therefore provides an
opportunity to non-invasively detect sites of inflammation/infection.
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3.3 Materials and Methods
3.3.1 Animal models
The programs and species evaluated in each program are listed in Table 3.1.  The
species, other than non-human primate, were selected based on the animal model
developed to study the disease-state targeted for each program.  The Institutional Animal
Care and Use Committee (IACUC) approved all experiments conducted with animals for
each of the programs.
Table 3.1 Number of pre-clinical animals and human subjects used for allometric
scaling in each Medical Imaging program.
Species/Program DPC-A80351 DMP-444 RP-517
Mouse 24
Guinea Pig 4
Rabbit 3 4
Dog 4 4
Primate 4 5 4
Human 4 20 6
3.3.1.1 DPC-A80351
Mouse- The c-Neu Oncomouse® is a spontaneous tumor bearing model that carries an
activated c-Neu oncogene driven by a mouse mammary tumor virus (MMTV) promoter.
Transgenic mice uniformly expressing the MMTV/c-neu gene develop mammary
adenocarcinomas (4 to 8 months postpartum) that involve the entire epithelium in each
gland.
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Dog- Canines used for blood pharmacokinetics were normal beagles and one
adenocarcinoma tumor-bearing mongrel.
Non-Human Primates- Four male Rhesus Monkeys (Macaca mulatta) were used for
evaluation of blood pharmacokinetics.
Human subjects- Pharmacokinetic analysis was conducted on biological samples from
cancer patients (n=4) enrolled in the DPC-A80351-101 Oncology Phase I clinical trial.
3.3.1.2 DMP-444
Rabbit- A rabbit carotid injury model was used for blood collection and pharmacokinetic
analysis. Male rabbits were anesthetized and the carotid artery stimulated with a 1m Amp
current for 20 minutes followed by test article administration.
Dog- Deep-vein thrombosis (DVT) induced dogs were used for blood kinetic studies.
Canine beagles were anesthetized with 35 mg/kg sodium pentobarbital, the jugular vein
isolated, a balloon catheter inserted and inflated, and thrombin infused for clot formation.
Non-Human Primates- Normal male Rhesus monkeys were used for evaluation of blood
pharmacokinetics.
Human subjects- Normal subjects enrolled in Phase I clinical trials were assessed for
blood pharmacokinetics.
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3.3.1.3 RP-517
Guinea pigs- A guinea pig peritonitis model was used for blood pharmacokinetics.
Guinea pigs were anesthetized i.m. with a 2:1 mixture of ketamine/xylazine.  A #10
trochar needle was used to introduce a 2 inch piece of umbilical string immersed in a 6%
sodium caseinate solution into the right flank.  The placement of the immersed string
served as the focal site for white blood cell recruitment over eighteen hours.
Rabbits- An e. Coli model of infection was used for blood kinetic evaluation. The rabbit
thigh was infected with e. Coli and 24 hrs later the test agent was administered.
Non-Human Primates- Normal Rhesus monkeys were used for evaluation of blood
pharmacokinetics.
Humans subjects- Normal subjects enrolled in Phase I clinical trials were assessed for
blood pharmacokinetics.
3.3.2 Species Dosing
DPC-A80351, DMP-444 and RP-517 were administered intravenously to animal
models and humans based on body weight according to Table 3.2.
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Table 3.2 Intravenous dose of DPC-A80351, DMP-444 and RP-517 administered to
animal models and humans.
Compound/
Species
Dose
mCi/kg
Body Weight
(kg)
DPC-A80351
Mouse 2.0 0.027
Dog 1.0 8.0
Primate 0.070 13.0
Human 0.39 70
DMP-444
Rabbit 1.0 2.8
Dog 1.0 9.6
Primate 1.0 11.6
Human 0.133 70
RP-517
Guinea Pig 0.8 0.5
Rabbit 1.0 2.2
Primate 1.0 15.2
Human 0.357 70
3.3.3 Scintigraphic Imaging
 In-house scintigraphic images were taken with a gamma camera (Park Isocam II,
Park Medical Systems, Lachine, Quebec) following administration of the test agent to
give a qualitative view of the distribution pattern and excretion route of the drug. Human
images were collected with various models of clinical gamma camera’s following GLP
(Good Laboratory Practice) procedures.
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3.3.4 Pharmacokinetic analysis
Blood samples were collected in anticoagulant from all species between 0-168 hrs
post-injection for counting radioactivity at time-points selected according to the protocol
design. An additional aliquot of blood was also centrifuged (2000xg, 15 min) to obtain
plasma for plasma protein binding analysis and metabolic profiling. Blood samples were
assayed for radioactivity using an LKB gamma counter (Wallac Inc, Gaithersburg, MD).
Aliquots were assayed in triplicate for blood.  Results from each sample replicate were
averaged and concentrations calculated using the following equation:
Radioactivity (µCi) = (Sample counts [counts per minute])/counter efficiency) /
(2.22x106 dpm)
Sample concentrations (uCi/mL) were corrected for isotope decay and adjusted for total
volume collected at each time-point using a customized excel spreadsheet.  This data was
then entered into WinNonlinTM Professional software (Pharsight Corp., Mountain View,
CA) and blood pharmacokinetics analyzed (Clearance of drug from the blood (CL),
Volume of distribution at steady state (Vdss), and terminal elimination half-life (t½)).
Blood clearance is determined by dividing the dose by the area under the curve (AUC)
which is calculated from zero to infinity using a linear trapezoidal method. Calculation of
the AUC from time zero to the last blood point collected should be at least 80% of the
AUC when compared to the AUC calculated from zero to infinity. This is important to
ensure the AUC value used in the calculation of clearance represents the majority of the
blood exposure.  Terminal elimination half-life was calculated using the last 2-4 blood
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points depending on the r-squared fit of the line and the inflection points between the
distribution and elimination phase of the blood curve. This defines the two-compartment
model that was used for all analyses. All species except mouse and guinea pig had full
blood curves collected from each animal/human. Mice and guinea pigs do not have
sufficient blood volume to collect enough timepoints for a full kinetic curve.
Pharmacokinetic parameters were calculated for each subject and reported as average ±
standard deviation (SD).  
3.3.5 Plasma protein binding
The Centrifree® Ultrafiltration Device (Millipore, Bedford, MA) was used to
separate free from protein bound drug (Figure 3.1). This system uses centrifugation
through a 30,000 molecular weight cutoff membrane to separate protein bound from
unbound drug.  The device is accurate, reproducible and has low non-specific binding for
the compounds tested.
Figure 3.1 Centrifree® Ultrafiltration Device
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For each sample collected for protein binding analysis, four aliquots (0.025 ml) of
plasma were transferred to separate polypropylene tubes for counting using an LKB
gamma counter (Perkin Elmer/Wallac, Gaithersburg, MD). An aliquot  (0.3 ml) of plasma
was transferred to a Centrifree® micropartition cartridge (n=4) and centrifuged at 2000 x
g for 11 minutes at RT.  Following centrifugation, 0.025 ml aliquots (n=4) of filtrate were
transferred to polypropylene tubes for gamma counting.  The compound was also diluted
in saline (~2mCi/ml) and assayed to determine non-specific binding.
The percent of compound bound to plasma proteins was calculated using the
following equation:
              Compound Total - Compound Unbound (filtrate)
% Bound =     ---------------------------------------------------------------- x 100
Compound Total
Compound total is radioactivity (dpm) in 0.025ml of sample before ultrafiltration and
Compound unbound is radioactivity (dpm) in 0.025ml of filtrate. Data are reported as the
mean ± SEM.
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3.3.6 Metabolic Stability analysis
Blood samples (0.5 mL) were treated with acetonitrile (2.0 mL) to precipitate
plasma proteins.  Following centrifugation at 2000 x g for 15 minutes, supernatants were
transferred to clean test tubes and dried under nitrogen at 37°C. An aliquot of the test
compound was also extracted to ensure the procedure did not cause any compound
degradation.
For high-pressure liquid chromatography (HPLC) analysis, 100 mL was injected for each
sample.  Reverse phase HPLC analysis of plasma was conducted using a Gamma Ram
radioactivity detector system (IN/US Systems, Inc., Tampa, FL) with a 0.1 mL flow cell
set at 10-500 channel range, and analog output of 7000.  A Hewlett Packard 1100
multisolvent HPLC delivery system (Hewlett Packard, Burlington, MA) and a
Multichrom data collection system (Thermo Lab Systems, Manchester, UK) were used.
HPLC conditions for the three programs are listed in Table 3.3.
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Table 3.3 HPLC conditions for Metabolic Stability analyses
DPC-A80351 DMP-444 RP-517
Column Zorbax C-18, 25cm Zorbax C-18, 25cm Zorbax C-18, 25cm
Temperature (°C) Ambient 50 Ambient
Flow (mL/min) 1 1 1
Mobile Phase A 25mM NH4 acetate, pH=7.4 25mM NaPo4, pH=8.0 25mM NaPo4, pH=6.0
Mobile Phase B 100% Acetonitrile 100% Acetonitrile 100% Acetonitrile
HPLC Gradient Time(min)          %B
0   2
25                     20
26                       60
35                       60
36                         2
45                         2
Time(min)          %B
0                       8
35                     14
38                     50
38                       8
Time(min)          %B
   0                           0
  20                       75
  30                       75
  31                         0
3.3.7 Allometric scaling
Allometric scaling employs log transformation of body weight and pharmacokinetic
parameters to extrapolate from animal models to humans. The following equation defines
allometric scaling:
Y = aWb
Y = physiological parameter (CL, t½, Vdss)
a = allometric coefficient
W = body weight
b = allometric exponent
The equation can also be expressed as:
Y = log a + b log W
(a = y intercept, b = slope)
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Each species body weight versus the pharmacokinetic parameter measured was
plotted on a log-log scale.  The human estimate is then determined through extrapolation
of the best-fit line drawn through the other species. In the case of clearance and volume
of distribution where values are expressed on a kilogram (kg) basis, the human estimate
is divided by an average human weight of 70 kg to give the result on a per kg basis.
When the plasma protein binding was used as a correction factor each
pharmacokinetic parameter within species was divided by the percent free fraction and
re-plotted on a log-log scale.  These adjusted points were then used to extrapolate to the
human free fraction estimate.  The measured human protein binding was then used to
adjust the estimated human free fraction back to a total value.
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3.4 Results
3.4.1 Pharmacokinetic
Frequent blood sampling was performed in a number of different species (mouse,
rabbit, guinea pig, dog, non-human primate and human) following radioligand
(DPC-A80351, DMP-444 and RP-517) administration. Radioactivity in blood was
determined by gamma counting.  Using customized excel spreadsheets radioactivity
counts were decay corrected back to the time of injection and expressed as uCi/ml blood.
Using the blood time-activity curves and WinNonlinTM Professional software (Pharsight
Corp., Mountain View, CA), pharmacokinetic parameters were determined and results
are listed in Table 3.4. For example, DPC-A80351 was administered to a 13-kg primate
at 0.07uCi/kg. Blood was collected at 2, 5 15, 30, 45, 60, 90 and 120 minutes post dose
and counted for radioactivity. The rate of DPC-A80351 clearance from the blood is
calculated (0.37 mL/min/kg) as well as terminal half-life (40.1 min), which is the time it
takes the drug concentration to decrease by half once steady state is achieved. The
volume of distribution into body water is also calculated (0.15 L/kg) to give an idea of
the extent the compound distributes out of the vasculature into extracellular or
intercellular water.
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Table 3.4 Pharmacokinetic results of DPC-A80351, DMP-444 and RP-517
following I.V. administration in pre-clinical models and humans.
Compound/
Species
Dose
mCi/kg
Body Weight
(kg)
t1/2
(terminal)
CL
(mL/min/kg)
Vdss
(L/kg)
DPC-A80351 (minutes)
Mouse 2.0 0.027 21.7 ± 7.6 6.12 ± 0.86 3.76 ± 1.74
Dog 1.0 8.0 21.8 ± 0.1 6.51 ± 1.34 6.0 ± 0.35
Primate 0.070 13.0 40.1 ± 9.9 0.37 ± 0.08 0.15 ± 0.05
Human 0.39 70 17.1 ± 4.0 0.43 ± 0.01 0.43 ± 0.08
DMP-444 (hr)
Rabbit 1.0 2.8 12.3 ± 0.1 0.41 ± 0.08 0.13 ± 0.05
Dog 1.0 9.6 16.5 ± 4.9 2.33 ± 0.33 0.25 ± 0.05
Primate 1.0 11.6 19.9 ± 3.9 0.11 ± 0.01 0.20 ± 0.01
Human 0.133 70 17.9 ± 3.2 0.22 ± 0.03 0.32 ± 0.05
RP-517 (hr)
Guinea Pig 0.8 0.5 2.3 0.89 0.13
Rabbit 1.0 2.2 2.7 ± 0.4 2.6 ± 0.5 0.37 ± 0.09
Primate 1.0 15.2 7.1 ± 0.8 0.44 ± 0.08 0.18 ± 0.03
Human 0.357 70 16.7 ± 9.0 0.40 ± 0.22 0.58 ±  0.31
t1/2 (terminal)= Terminal half-life; CL=Blood clearance; Vdss
=Volume of distribution at
steady state.  Values are expressed as mean ± SD (standard deviation)
The pharmacokinetics for these agents showed a range of characteristics. These
included a short half-life for DPC-A80351 in all species versus DMP-444 that had a long
half-life and RP-517 that had a half-life that was strongly species dependent.
DPC-A80351 had a greater range of both clearance and volume of distribution between
the species than either of DMP-444 or RP-517 which correlates with the extent of protein
binding in each species as discussed in section 3.4.2.  These differences provide a good
opportunity to examine the usefulness of allometric scaling in varied radiopharmaceutical
imaging agents.
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3.4.2 Plasma Protein Binding
Plasma protein binding was determined from in vivo blood samples taken 15
minutes following radioligand administration.  Bound and free ligand were separated by
centrifugation through a molecular weight cut-off filter.  Plasma protein binding results
are shown in Table 3.5.   DMP-444 was moderately protein bound in rabbits, primates
and humans but showed lower binding in the dog.  In contrast, DPC-A80351 showed low
protein binding in mice and dogs but considerably higher protein binding in the primate
and human.  Unfortunately data was only available for RP-517 protein binding in the
rabbit.
Table 3.5 In vivo Plasma Protein Binding for species at 15 minutes post-injection for
each Medical Imaging program.
Species/Program DMP-444 *RP517 DPC-A80351
Mouse - - 28.4 ± 8.3
Guinea Pig - NA -
Rabbit 70.0 ± 3.9 32.0 ± 12.1 -
Dog 40.9 ± 2.0 - 13.0 ± 1.1
Primate 83.0 ± 4.7 NA 78.4 ± 3.4
Human 83.0 ± 0.6 NA 83.9 ± 5.7
 *Plasma protein binding assessed in rabbit only
3.4.3 Metabolic Stability
In vivo stability was determined by HPLC separation and radiodetection of blood
samples taken following in vivo administration. Results for each of the compounds tested
are listed in Table 3.6.  Stability of all compounds in all species tested was > 95%
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radiochemically pure up to 15 minutes post-injection. Blood samples analyzed at later
times were below the limit of radiochemical detection for 1% metabolites.
Table 3.6 In vivo blood stability through 15 minutes post-injection for species in
each Medical Imaging program.
% Radiochemical purity
Species/Program DMP-444 RP-517 DPC-A80351
Mouse - - > 95
Guinea Pig - > 95 -
Rabbit > 95 > 95 -
Dog > 95 - > 95
Primate > 95 > 95 > 95
Human > 95 > 95 > 95
3.4.4 Scintigraphic Imaging
Scintigraphic images were taken with a gamma camera following administration
of the test agent to give a qualitative view of the distribution pattern and excretion route
of the drug.  Representative images of non-human primate and one other species from
each program are shown in Figures 3.2-3.7.  Figure 3.2 and Figure 3.3 present mouse and
primate images administered DPC-A80351, respectively.  Notice the high uptake in the
mouse tumors.
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                0.5 hr Post Injection   1 hr Post Injection             2 hr Post Injection
Figure 3.2 Representative scintigraphic images of DPC-A80351 (40 mCi/kg) in
c-neu Oncomouse® over 2 Hours
Liver
Intestines
Kidney
Bladder
Figure 3.3  Representative whole-body anterior images of monkey at two hours and
24 hours after the administration of 0.5 mCi /kg DPC-A80351.
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Both images show a pattern of predominantly renal excretion with some
hepatobiliary clearance in the primate. Previous studies have shown a similar pattern of
tissue distribution and renal clearance in the c-neu Oncomouse. (Onthank et al., 2004 –
Appendix I).
Figure 3.4 and Figure 3.5 represent canine and primate images administered
DMP-444, respectively.  Images show a mixture of renal and hepatobilary clearance in
both species.  Notice the high uptake in the thrombosis induced in the canine carotid
arteries of the neck.
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Carotid
Artery
Liver
Intestines
Bladder
Figure 3.4 Representative scintigraphic image of the canine deep vein thrombosis
(DVT) model 60 minutes post-injection following i.v administration of 0.3
mCi/kg DMP-444.
Liver
Gall Bladder
Urinary Bladder
Figure 3.5 Typical whole-body image of rhesus monkey administered DMP 444  at 1
mCi/kg,i.v.  Depicted are the anterior (left) and posterior (right), whole
body images at 60 min postinjection.
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DMP-444 is excreted both renally and hepatobiliary while RP-517 is hepatobiliary
cleared.  Figure 3.6 and Figure 3.7 show representative images of rabbit and primate
following administered of RP-517, respectively.  Both images show predominantly
hepatobiliary clearance with no visualization of the kidneys. Notice the high uptake in
focal infection of the thigh.
Liver
Intestine
No Bladder
Infection site
Figure 3.6 Image of RP517 in the Rabbit e. Coli model of infection.  RP517 was
administered at a dose of 1 mCi/kg,i.v. and uptake monitored over a
period of 4 hr postinjection.
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Figure 3.7 Representative scintigraphic image of a non-human Primate following i.v.
administration of 0.6 mCi/kg RP-517. Images were taken at 0.5, 1 and 4hr post-injection.
Each compound exhibits a good pharmacokinetic profile with respect to the
clearance route from the body that allows diagnostic imaging of the intended target.
Similar distribution and clearance patterns seen in primates were observed in humans for
all compounds.  These three radiopharmaceuticals provide a range of excretion patterns
to assess how well allometric scaling predicts for different routes of excretion.
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3.4.5 Allometric Scaling
Allometric scaling from animals to human for blood clearance, half-life
and volume of distribution was conducted for DPC-A80351, DMP-444 and RP-517.
Predicted values in the human, before and after applying plasma protein binding
correction, were compared to the observed values. The percent error was then calculated
between the observed and predicted values.
3.4.6 Blood Clearance
Blood clearance (CL) of DPC-A80351 for each animal model was plotted through
allometric scaling pre (Figure 3.8) and post (Figure 3.9) correction for plasma protein
binding to predict for human clearance. The extrapolated line fit (R2) was better when
corrected for protein binding and the prediction of blood clearance improved from 109%
to 4.7% of the observed value (Table 3.7).
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Figure 3.8 Allometric scaling of Blood Clearance for DPC-A80351.
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Figure 3.9 Allometric scaling of Blood Clearance for DPC-A80351 corrected for
Plasma Protein Binding
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Table 3.7 Predicted Versus Observed Clearance in Humans Using Allometric
Scaling and Correction Factors.
Drug Observed CL
(ml/min/kg)
Predicted CL
Pre-
Correction
(ml/min/kg)
% Error
Pre-
Correction
Predicted CL
Post-
Correction
(ml/min/kg)
% Error
Post-
Correction
Species
used
DPC-
A80351
0.43 ± 0.01 0.90 109 0.41 4.7 m, d,
rhmk
DMP-444 0.22 ± 0.03 0.39 77 0.24 9.0 rab, d,
rhmk
RP-517 0.40 ± 0.22 0.45 12.5 0.45 12.5 gp,rab,
rhmk
m = mouse, r = rat, gp = guinea pig, d = dog, rab = rabbit, rhmk = rhesus monkey
% Error = (observed-predicted)*100/observed
Similarly, blood clearance of DMP-444 for each animal model was plotted
through allometric scaling pre (Figure 3.10) and post (Figure 3.11) correction for plasma
protein binding to predict for human clearance. The extrapolated line fit (R2) was better
when corrected for protein binding and the prediction of blood clearance improved from
77% to 9.0% of the observed value (Table 3.7).
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Figure 3.10 Allometric scaling of Blood Clearance for DMP-444.
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Blood clearance of RP-517 for each animal model was plotted through allometric
scaling pre (Figure 3.12) and post (Figure 3.13) correction for plasma protein binding to
predict for human clearance. The corrected clearance values reflected the assumption that
protein binding was the same in all species and therefore changed the scale of the plots,
however resulted in the same values.  The predicted clearance was within 13% of the
observed, which is excellent, however may have improved as it did in the other two
programs if protein binding data was available (Table 3.7).
65
0.45
6.665.70
31
0.1
1
10
100
0.1 1 10 100
BW (kg)
C
L
 (m
l/m
in
)
GP monkey Rabbit human
Estimated Human CL= 0.45 ml/min/kg
CL=a*BWb,     a= 1.26
b= 0.76
R2= 0.73
Figure 3.12 Allometric scaling of Blood Clearance for RP-517.
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3.4.7 Half-life
Terminal half-life of DPC-A80351 for each animal model was plotted through
allometric scaling pre (Figure 3.14) and post (Figure 3.15) correction for plasma protein
binding to predict for human. The extrapolated line fit (R2) didn’t improve when
corrected for protein binding, however the prediction of half-life improved from 96% to
25.7% of the observed value (Table 3.8).
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Figure 3.14 Allometric scaling of terminal half-life (t½) for DPC-A80351.
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68
Table 3.8 Predicted Versus Observed Half-life in Humans Using Allometric Scaling
and Correction Factors.
Drug Observed
T½
Predicted
T½
Pre-
Correction
% Error
Pre-
Correction
Predicted
T½
Post-
Correction
% Error
Post-
Correction
Species used
DPC-
A80351
17.1 ± 4.0
(min)
33.5
(min)
96 21.5
(min)
25.7 m, d, rhmk
DMP-444 17.9 ± 3.2
(hr)
32.2
(hr)
80 16.0
(hr)
10.6 rab, d, rhmk
RP-517 16.7 ± 9.0
(hr)
10.9
(hr)
34.7 10.9
(hr)
34.7 gp, rab,
rhmk
m = mouse, r = rat, gp = guinea pig, d = dog, rab = rabbit, rhmk = rhesus monkey
% Error = (observed-predicted)*100/observed
Similarly, half-life of DMP-444 for each animal model was plotted through
allometric scaling pre (Figure 3.16) and post (Figure 3.17) correction for plasma protein
binding to predict for human. Although the extrapolated line fit (R2) also didn’t improve
when corrected for protein binding, the prediction of half-life improved from 80% to
10.6% of the observed value (Table 3.8). Because the non-human primate has similar
protein binding as the human, the extrapolated line was skewed toward a better estimate
of the human half-life.
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Half-life of RP-517 for each animal model was plotted through allometric scaling
pre (Figure 3.18) and post (Figure 3.19) correction for plasma protein binding to predict
for human. The corrected half-life values reflected the assumption that protein binding
was the same in all species and therefore changed the scale of the plots, however resulted
in the same values.  The predicted half-life was within 35% of the predicted, which may
have improved as it did in the other two programs if protein binding data was available
(Table 3.8).
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Figure 3.18 Allometric scaling of terminal half-life (t½) for RP-517.
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3.4.8 Volume of Distribution
Volume of distribution of DPC-A80351 for each animal model was plotted
through allometric scaling pre (Figure 3.20) and post (Figure 3.21) correction for plasma
protein binding to predict for human. The extrapolated line fit (R2) improved when
corrected for protein binding, however the prediction of Vdss changed from 23% to
44.1% of the observed value (Table 3.9). This small change further from the predicted
value still results in a reasonable estimate of Vdss.
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Figure 3.20 Allometric scaling of Volume of distribution (Vdss) for DPC-A80351.
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Table 3.9 Predicted Versus Observed Vdss in Humans Using Allometric Scaling and
Correction Factors.
Drug Observed
Vdss
(L/kg)
Predicted
Vdss
Pre-
Correction
(L/kg)
% Error
Pre-
Correction
Predicted
Vdss
Post-
Correction
(L/kg)
% Error
Post-
Correctio
n
Species
used
DPC-
A80351
0.43 ± 0.08 0.53 23 0.24 44.1 m, d,
rhmk
DMP-444 0.32 ± 0.05 0.46 44 0.28 12.5 rab, d,
rhmk
RP-517 0.58 ± 0.31 0.25 57 0.25 57 gp, rab,
rhmk
m = mouse, r = rat, gp = guinea pig, d = dog, rab = rabbit, rhmk = rhesus monkey
% Error = (observed-predicted)*100/observed
Volume of Distribution of DMP-444 for each animal model was plotted through
allometric scaling pre (Figure 3.22) and post (Figure 3.23) correction for plasma protein
binding to predict for human Vdss. The extrapolated line fit (R
2) was slightly worse when
corrected for protein binding, however the prediction of Vdss improved from 44% to
12.5% of the observed value (Table 3.9).
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Volume of distribution of RP-517 for each animal model was plotted through
allometric scaling pre (Figure 3.24) and post (Figure 3.25) correction for plasma protein
binding to predict for human. The corrected Vdss values reflected the assumption that
protein binding was the same in all species and therefore changed the scale of the plots,
however resulted in the same values.  The predicted Vdss was within 57% of the
predicted, which may have improved as it did in the other two programs if protein
binding data was available (Table 3.9).
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Figure 3.24 Allometric scaling of Volume of distribution (Vdss) for RP-517.
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The pharmacokinetic predictions for humans based on the non-corrected
allometric scaling were in the range of 13 to 109% of the measured values.  These
estimates improved further when values were adjusted for protein binding (5-57% of
predicted value).  Improvements were most apparent for DPC-A80351, which had a
strong species dependency to the protein binding.  Smaller effects were present with RP-
517 where very limited protein binding data was available.
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3.5 Discussion
For the three compounds examined, allometric scaling without correction
predicted within 109% (often considerably better) of the measured pharmacokinetic
parameters. If these pharmacokinetic parameters were then used for calculating the
optimum imaging dose in human, the predicted dose could be 100% different since dose
is directly proportional to the change in blood clearance (Dose= Cl x AUC). Allometric
scaling corrected for protein binding improves the predicted dose within 13%. In contrast
to body weight scaling, the dose to produce the same pharmacokinetic value if scaled on
a meter squared body surface area results in a 20–40 fold over-prediction of clearance in
the three programs.  Whereas body surface area typically reflects differences in
metabolism versus differences in body weight and is often used for conversion and
calculations in safety toxicology studies, it doesn’t appear to work particularly well for
predicting pharmacokinetics in these programs.
Plasma protein binding was seen to differ markedly with DPC-A80351 from
species to species.  Since clearance, distribution and half-life are all dependent on the
amount of drug available versus the amount bound, protein binding has the potential to
markedly influence predictions from species to species.  This was demonstrated by the
marked improvement in the prediction of pharmacokinetic parameters by allometric
scaling for DPC-A80351 following correction for protein binding.  The protein binding
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correction had less of an impact on the predictions made for DMP-444.  This reflects the
smaller range between the different species in protein binding.  The minimal impact for
RP-517 was expected since the only protein binding value was in the rabbit, therefore, no
species selective adjustments were achieved.
If protein binding and/or metabolic stability are not considered when calculating
blood clearance, it would not be clear if the drug concentration reflects intact drug or
metabolic fragments and to what extend they are bound to plasma proteins. Various
combinations of these unknown variables could surely influence interpretation of the
pharmacokinetic data.  Correcting for pharmacokinetic differences using metabolic
stability is difficult when only one or two single time-points are taken early in the
distribution phase of the kinetic curve.   At the time a blood sample is counted for
radioactivity, the counts represent all radioactivity, which includes parent drug and all
metabolic fragments.  These fragments may also be bound in different amounts to plasma
proteins.  Since metabolic stability was > 95% radiochemical purity in all species across
the programs, there was no need for correction.
The terminal half-life of compound in circulation may be difficult to estimate if
blood is not sampled long enough post-injection to capture at least 80% of the total area
under the blood concentration-time curve. If multiple blood samples are not collected in
the terminal elimination phase to clearly define the slope of the line, the half-life may be
over or under estimated. In the current three programs this was not an issue and the
results reflected a percent error between predicted and observed values of < 35%.
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Another important consideration in allometric scaling is the selection of species
used in the analysis.  It is not only important to have 2-3 species for accurate predictive
scaling, it is also necessary to ensure that species size varies enough in body weight to
control the slope of the line for predicting a given pharmacokinetic parameter. All three
programs discussed in this chapter had a wide range of weights for the species tested. If
the animals used for modeling are all close in body weight, the slope of the line drawn for
predicting a 70-kg human could be poorly defined because of a small range of data points
and result in a poor prediction as described in chapter one, section 1.1.7.  It is important
therefore to include a small animal species (i.e. mouse, rat) in the extrapolation, which is
typically done for toxicokinetic studies anyway. Recent data published by Tang et al,
2005, suggests that certain species or combination of species used in experimental
modeling are better for predicting pharmacokinetic parameters than others and note that
the number of animals tested within a species can add variability to the extrapolated line
fit. In other words, if one or two species in particular have shown previous similarities to
human in vitro results or the literature has suggested a model that is similar in drug
disposition to the human for a similar drug, more emphasis should be placed on this
model.  Increased replicates or more weighting should also be considered. It is also worth
noting that allometric scaling using all species predicted more accurately than estimating
from primate alone in all three programs.
Based on the results of the research described in this dissertation, blood clearance
in the human can be predicted with reasonable accuracy from animal models using
allometric scaling. This does not ensure that the blood exposure of the drug to the target
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in humans will be sufficient to deliver enough to bind to the target and elicit a response
similar to that observed in the animal models. Thus, the next challenge is to use this data
to select a dose that will provide the same binding to the target as observed in the animal
models.  To accomplish this, it is assumed that the same blood exposure of the compound
in the animal models would need to be achieved in humans to obtain similar target
uptake.  In other words, the total blood exposure (area under the blood concentration-time
curve) should be the same in animals as in humans assuming similar interactions between
the drug and target are necessary for uptake.  If the same blood exposure is required, then
the human dose can be calculated using the formula, Dose = Cl x AUC, where Cl is the
predicted human clearance and AUC is the area under the curve from the animal model
blood concentration-time curves. Based on the average AUC observed for the two disease
state animal models in the Oncology program (mouse and dog, 0.33 and 0.15
uCi*min/ml, respectively) the human dose required to achieve the same AUC using the
calculated allometric clearance value would be 0.1 uCi/kg. The actual dose administered
in the clinical trials was 0.39 uCi/kg which is 3.9 times the dose calculated to
successfully deliver enough drug to its target for the expected response. The actual
imaging data from the clinical trials suggested limited tumor uptake from the few patients
in the trial (n=4), however the tumor size and type may have explained low uptake as
opposed to not enough drug delivered.  Alternatively, the distribution and number of
receptors in the human tumor versus the animal tumor could have been sufficiently
different to explain the difference. Similarly, based on the average AUC observed for the
two disease state animal models in the Infection program (guinea pig and rabbit, 0.90 and
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0.38 uCi*min/ml) the human dose required to achieve the same AUC and using the
calculated allometric clearance value would be 0.29 uCi/kg. The actual dose administered
in the clinical trials was 0.36 uCi/kg which is 1.2 times the dose calculated to
successfully deliver enough drug to its target for the expected response.  The Thrombus
program showed the predicted human dose was high enough (0.13 uCi/kg) based on the
AUC exposure in the dog model (0.43 uCi*min/ml), however 4.4 fold too low based on
the AUC exposure in the rabbit model (2.4 uCi*min/ml).  These data indicate that human
doses administered in the clinical programs were sufficient to deliver enough drug to its
target to elicit a response assuming AUC in animal models are predictive of AUC in
humans.
Allometric scaling of body weight corrected to free fraction of drug in the blood
appears to accurately predict drug clearance and an efficacious dose in human. Direct
body weight scaling was mentioned early in the discussion, however other methods that
may provide good pharmacokinetic estimates such as allometric scaling of body surface
area (BSA) are also applicable.  Animal models used for pharmacokinetic analysis are
typically smaller than humans and usually have higher metabolic rates.  Therefore, body
surface area is often used for extrapolation based on the assumption that it corrects for
differences in metabolism better than body weight (Kwiatkowski R., 1999).   If body
surface area calculations were used to predict dose in humans in the medical imaging
programs, an overestimation of dose would be calculated as mentioned earlier.
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The literature reviews many scaling methods for predicting pharmacokinetics as
reviewed in chapter one. Often, pharmacokinetic data are compiled from the literature
and used to make scaling predictions with minimal, if any, assessment of protein binding
or metabolic stability data to help characterize the fate of the drug in circulation.  This
may be an issue with the various methods that have not optimally predicted
pharmacokinetic parameters. Protein binding and metabolic stability results are very
important to consider when predicting human pharmacokinetics.
Accurate prediction of blood clearance and volume of distribution in humans for a
particular drug is important for calculating the total exposure from a given amount of
compound administered. This is essential, when considering selection of the first dose in
human, to ensure circulating blood concentrations are safe and at high enough
concentrations to target the disease process (Benet et al., 1984). Based on human dose
estimates from the allometric scaling, doses administered in the clinical programs were
sufficient to deliver enough drug to its target to elicit a response, assuming drug exposure
in animal models is the same exposure required in humans. This may be a dangerous
assumption considering possible differences in the target, including: receptor
density/specificity, morphology and other characteristics that may influence drug
targeting, however many of these concerns may be addressed using in vitro assay testing.
Providing this additional pharmacokinetic information to the regulatory agencies will
help support the proposed level of drug for administration.  Highly predictive results are
expected from animal models not only qualitatively but quantitatively as well.  This
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continues to be a challenging problem.  Humans are highly diverse both biologically and
genetically, which makes extrapolation even more difficult.
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4. CHAPTER 4
Prediction of “First Dose in Human” for an Atherosclerotic Plaque Targeted
Radiopharmaceutical Imaging Agent Based on Allometric Scaling of
Pharmacokinetics in Pre-Clinical Animal Models
4.1 Summary
Allometric scaling corrected for plasma protein binding was applied to
pharmacokinetic data derived from an atherosclerotic plaque targeted
radiopharmaceutical imaging agent, RP845-Tc-99m, currently in development.  Blood
clearance (CL), terminal half-life (t½) and volume of distribution (Vdss) were determined
for mouse, rat and rabbit, then plotted through allometric scaling without correction
factors to predict non-human primate pharmacokinetics.  Differences between predicted
versus observed non-human primate Cl, t½ and Vdss, before applying correction factors,
were 40%, 52% and 8%, respectively.  Following allometric scaling correcting for
plasma protein binding, predicted versus observed Cl, t½ and Vdss results were 12%, 3%
and 38%, respectively. Allometric scaling alone predicted non-human primate
pharmacokinetics from other animal models within 52% overall, however following
correction for free fraction of the drug, predictions achieved an accuracy of < 38% of the
observed values.  Since blood clearance is considered one of the key parameters in
predicting human dose, the improvement from 40% to 12% was significant. The
metabolic stability in all species was similar and, therefore, not used as a correction
factor.
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Mouse, rat, rabbit and non-human primate were then used for allometric scaling
with plasma protein binding correction to predict human CL, t½ and Vdss.  The predicted
values were 7.6 mL/min/kg, 70.6 minutes and 0.87 L/kg for CL, t½ and Vdss,
respectively. Using the predicted blood clearance in human through allometric scaling, a
typical RP845-Tc-99m dose of 25 mCi/subject would be ten times below the dose
required to image atherosclerotic plaque in humans based on data from the animal model
images. This represents a good example of how predicting accurate blood clearance of a
compound in humans through corrected allometric scaling would help evaluate the
compound’s targeting potential and success of scintigraphic imaging. This information
would also help guide structural modifications to optimize pharmacokinetics and provide
an indication of the expected compound delivery to the target in clinical trials.
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4.2 Introduction
The atherosclerotic plaque-imaging agent is a technetium-99m
radiopharmaceutical under development to allow the identification of patients at high risk
of coronary events by targeting and imaging atherosclerotic lesions.  Atherosclerosis is a
disease of blood vessels involving cellular and morphological changes of the vessel wall
that may lead to coronary thromboses resulting from rupture of the fibrous cap of the
plaque.  Literature now supports the concept that the atherosclerotic plaques can undergo
continuous and dynamic remodeling and displays considerable metabolic activity
(Bentzon et al., 2003; Sosnovik et al., 2002).  This presents opportunities to develop
imaging agents that may identify when plaques are at high risk (vulnerable plaques) of
rupturing and precipitating acute myocardial infarction or unstable angina. Currently,
there are no accurate methods of non-invasively assessing the location or degree of
atherosclerotic plaque burden in the coronary vessels.
The vulnerable plaque research project described in this chapter examines the use
of allometric scaling corrected for plasma protein binding to better utilize the data
available from animal models to predict a safe and efficacious clinical dose.
Pharmacokinetic data from three animal models will be used to predict pharmacokinetics
in the non-human primate and assessed for accuracy of the prediction. Human
pharmacokinetics will then be determined using all the species.
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4.3 Materials and Methods
4.3.1 RP845-Tc-99m
RP845-Tc-99m is a low molecular weight, hydrophilic 99mTc containing chelate
administered as a single intravenous dose.  A localization sequence in RP845-Tc-99m
causes the molecule to be preferentially retained in plaque bearing arterial walls and have
low association and rapid clearance from other non-target tissues. These characteristics
make it an ideal candidate for an imaging agent.
4.3.2 Animal models
The species evaluated in this program are listed in Table 4.1. The mouse and
rabbit are well-defined atherosclerotic plaque models used in the literature and were
selected on this basis (Johnson et al., 2001; Rosenfeld et al., 2000; Johnstone et al., 2001;
Feldman et al., 2001).  The rat will be used for toxicology studies and was therefore
chosen as the third species used for predicting non-human primate pharmacokinetics. The
Institutional Animal Care and Use Committee (IACUC) has reviewed protocol
procedures and approved all experiments conducted with animals.
90
Table 4.1 Pre-clinical animal models used for allometric scaling of RP845-Tc-99m.
Species # Animals
Mouse 3
Rat 3
Rabbit 5
Non-human Primate 1
Mouse- The apolipoprotein E (ApoE) knockout mouse is a model of
hypercholesterolemia that develops atherosclerotic lesions in the brachiocephalic artery,
the aortic arch and the abdominal aorta.  Mice are fed a high-fat diet to accelerate plaque
formation and administered test compounds between 37- 41 weeks on diet.
Rat- Normal Sprague-Dawley rats were used for blood pharmacokinetics.
Rabbit- Atherosclerosis was induced in New Zealand White male rabbits (3 kg) with
aortic balloon endothelial injury followed by feeding a 0.5% cholesterol diet for 22
weeks.
Non-Human Primate- A male Rhesus Monkey (Macaca mulatta) was used for
evaluation of blood pharmacokinetics.
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4.3.3 Species Dosing
RP845-Tc-99m was administered as a single, bolus intravenous dose to
animals based on body weight according to Table 4.2.
Table 4.2 Intravenous dose of RP845-Tc-99m administered to animal models.
Species Dose
(mCi/kg)
Body Weight
(kg)
Mouse 5.4 0.025
Rat 0.4 0.36
Rabbit 1.3 3.4
Non-human Primate 1.2 5.4
4.3.4 Scintigraphic Imaging
 Scintigraphic images were taken with a gamma camera (Park Isocam II, Park
Medical Systems, Lachine, Quebec) following administration of the test agent to give a
qualitative view of the distribution pattern and excretion route of the drug.
4.3.5 Blood sample collection
Blood samples were collected into sodium heparin anticoagulant from all species
between 0-168 hrs post-injection at timepoints selected according to the protocol design.
All samples were weighed and assayed for radioactivity.  An aliquot of blood was also
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centrifuged (2000xg, 15 min) to obtain plasma for plasma protein binding analysis and
metabolic profiling.
4.3.6 Pharmacokinetic analysis
Blood samples were assayed for radioactivity using an LKB gamma counter
(Wallac Inc, Gaithersburg, MD).  Aliquots were assayed in triplicate for all blood
samples.  Results from each sample replicate were averaged and concentrations
calculated using the following equation:
Radioactivity (µCi) = (Sample counts [counts per minute])/counter efficiency) /
(2.22x106 dpm)
Sample concentrations (uCi/mL) were corrected for isotope decay and adjusted for total
volume collected at each timepoint.  Blood pharmacokinetic analysis was performed
using WinNonlinTM Professional software (Pharsight Corp., Mountain View, CA).
Clearance of drug from the plasma (CL), Volume of distribution at steady state (Vdss),
and Elimination half-life (t½) were calculated.
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4.3.7 Plasma protein binding
For each sample collected for protein binding analysis, four aliquots (0.025 ml) of
plasma were transferred to separate polypropylene tubes for counting using an LKB
gamma counter (Perkin Elmer/Wallac, Gaithersburg, MD). An aliquot  (0.3 ml) of plasma
was transferred to a Centrifree® micropartition cartridge (n=4) and centrifuged at 2000 x
g for 11 minutes at RT. After centrifugation, 0.025 ml aliquots (n=4) of filtrate were
transferred to polypropylene tubes for gamma counting. The compound kit was also
diluted in saline (~2mCi/ml) and assayed to determine non-specific binding.
Data Analysis
The percent of compound bound to plasma proteins was calculated using the following
equation:
             Compound Total - Compound Unbound (filtrate)
% Bound =     ---------------------------------------------------------------- x 100
           Compound Total
Compund total is radioactivity (dpm) in 0.025ml of sample before ultrafiltration and
Compound unbound is radioactivity (dpm) in 0.025ml of filtrate. Data are reported as the
mean ± SEM.
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4.3.8 Metabolic Stability analysis
Blood samples (0.5 mL) were treated with acetonitrile (2.0 mL) to precipitate
plasma protiens.  Following centrifugation at 2000 x g for 15 minutes, supernatants were
transferred to clean test tubes and dried under nitrogen at 37°C. Samples were
reconstituted and 100 uL used for high-pressure liquid chromatography (HPLC) analysis,.
Reverse phase HPLC analysis of plasma was conducted using a Gamma Ram
radioactivity detector system (IN/US Systems, Inc., Tampa, FL) with a 0.1 mL flow cell
set at 10-500 channel range, and analog output of 7000.  A Hewlett Packard 1100
multisolvent HPLC delivery system (Hewlett Packard, Burlington, MA) and a
Multichrom data collection system (Thermo Lab Systems, Manchester, UK) were used.
The flow rate through the HPLC column (Zorbax RX-C18, 250 x 4.6 mm) and guard
column (Zorbax C18, 12.5 mm x 4.6 mm) was 1 mL/minute.  Deproteinized plasma
extracts were analyzed using a gradient of 25 mM ammonium acetate/acetonitrile over
30 minutes. The column was equilibrated for 10 minutes with the initial conditions prior
to the next injection.
An aliquot of the test compound was also subjected to the extraction procedure
and used to determine if HPLC peaks in samples were present in the collected sample or
formed during the extraction procedure.
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4.3.9 Allometric scaling
Allometric scaling employs log transformation of body weight and
pharmacokinetic parameters to extrapolate from animal models to humans. The equation
is defined in chapter three, section 3.3.7.
Each species body weight versus the pharmacokinetic parameter measured is
plotted on a log-log scale.  The non-human primate or human estimate is then determined
through extrapolation of the best-fit line drawn through the other species. In the case of
clearance and volume of distribution where values are expressed on a kilogram (kg)
basis, the non-human primate or human estimate is divided by the body weight to express
the result per kg.
When the plasma protein binding was used as a correction factor each
pharmacokinetic parameter within species was divided by the percent free fraction and
re-plotted on a log-log scale.  These adjusted points were then used to extrapolate to the
non-human primate or human free fraction estimate.  The measured protein binding was
then used to adjust the estimated non-human primate or human free fraction back to a
total value.
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4.4 Results
4.4.1 Pharmacokinetic results
Pharmacokinetic results for RP845-Tc-99m in pre-clinical animal models
are presented in Table 4.3.
Table 4.3 Pharmacokinetic results of RP845-Tc-99m following I.V. administration
in pre-clinical models. Values are expressed as mean ± SD (standard
deviation)
Species Dose
(mCi/kg)
Body
Weight
(kg)
t1/2
(terminal)
(minutes)
CL
(mL/min/kg)
Vdss
(L/kg)
AUC
(mCi*min/mL)
Mouse 5.4 0.025 60.3 7.11 0.58 0.76
Rat 0.39 0.36 66.6 ± 1.2 12.9 ± 0.14 0.96 ± 0.37 0.03
Rabbit 1.3 3.4 106.5 ± 11.4 3.63 ± 0.86 0.50 ± 0.07 0.36
Non-
human
Primate
1.2 5.4 68.6 8.2 0.66 0.15
t1/2 (terminal)= Terminal half-life; CL=Blood clearance; VD
 
ss
=Volume of distribution at steady state,
AUC=Area under the blood concentration-time curve
The pharmacokinetics indicate rapid blood clearance in all species as evident
from the short half-life in all species. The volume of distribution suggests hydrophilic
characteristics with distribution into extracellular and intercellular compartments. All
species except rabbit clear the blood faster than kidney filtration alone, based on the
glomerular filtration rates for mouse (14 mL/min/kg), rat (5.2 mL/min/kg), rabbit (3.1
mL/min/kg) and non-human primate (2.1 mL/min/kg), as reported by Davies and co-
workers (1993).  Hepatobiliary clearance as well as renal clearance is evident in mouse
and non-human primate images shown in the scintigraphic images results section.
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4.4.2 Plasma Protein Binding
Plasma protein binding results are shown in Table 4.4. Percent bound to proteins
was low in all species examined.
Table 4.4 In vivo Plasma Protein Binding of RP845-Tc-99m at 15 minutes post-
injection in mouse, rat, rabbit and non-human primate.
Species % Protein Bound
Mouse 20.3
Rat 54.1
Rabbit 41.5
Primate 27.3
The in vitro binding for human plasma when incubated for 15 minutes was
20.1%. This is similar to the in vivo value seen in the NHP and mouse. Previous studies
have indicated that in vitro values are often comparable to those measured in vivo.
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4.4.3 Metabolic Stability
In vivo blood stability for each of the compounds tested is listed in Table 4.5.
Stability of all compounds within all species was 71-78% parent compound up to 15
minutes post-injection.
Table 4.5 In vivo blood stability of RP845-Tc-99m through 15 minutes post-
injection in mouse, rat, rabbit and non-human primate.
Species/Program % RP845
Mouse 72
Rat 78
Rabbit 76
Non-human primate 71
Radiochemical purity of RP845 for in vitro human plasma determinations at 15
minutes of incubation was 72%. Pharmacokinetic predictions were not corrected for
metabolic stability since there was equivalent stability in all species tested.
4.4.4 Scintigraphic Imaging
Scintigraphic images were taken with a gamma camera following administration
of the test agent to give a qualitative view of the distribution pattern and excretion route
of the drug.  Mouse, rabbit and non-human primate images following administration of
RP845-Tc-99m are depicted in Figure 4.1, Figure 4.2 and Figure 4.3, respectively.
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Kidneys
Bladder
Figure 4.1 Representative scintigraphic image of the ApoE mouse model at 1hr post-
injection following i.v administration of 20 mCi/kg RP845-Tc-99m.
Bladder
Kidneys
Plaque in
Aorta
Figure 4.2 Representative scintigraphic image of RP845-Tc-99m at 1 hr post
injection in the New Zealand Rabbit plaque model.
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Figure 4.3 Representative whole-body anterior images of a non-human primate at 2hr
post-injection of 1.0 mCi /kg RP845-Tc-99m.
RP-845-Tc-99m exhibits an excellent pharmacokinetic profile for an
atherosclerotic plaque diagnostic-imaging agent with rapid clearance from the body and
predominantly renal excretion. RP-845-Tc-99m does, however, show slight qualitative
differences in excretion between the species. Mouse exhibits mainly renal excretion with
some evidence of hepatobiliary clearance, rabbit shows primarily renal clearance and
non-human primate excretes through both routes.  These three models suggest a range of
excretion patterns as evident from the blood clearance values and scintigraphic images.
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The models provide data to assess how well allometric scaling predicts pharmacokinetics
with different routes of excretion in the species.
4.4.5 Allometric Scaling
Allometric scaling for blood clearance, half-life and volume of distribution
was calculated for non-human primate using data from the mouse, rat and rabbit (Table
4.6).
Table 4.6 Predicted Versus Observed Pharmacokinetics in Non-Human primate
Using Allometric Scaling and Protein Binding Correction.
Parameter Observed Predicted
Pre-
Correction
% Error
Pre-
Correction
Predicted
Post-
Correction
% Error
Post-
Correction
Species
used
CL
(ml/min/kg)
8.2 4.9 40 7.2 12 m, r, rab
T1/2
(min)
68.6 104.1 52 70.7 3 m, r, rab
VDss
(L/kg)
0.66 0.61 8 0.91 38 m, r, rab
m = mouse, r = rat, rab = rabbit
% Error = (observed-predicted)*100/observed
The percent error following correction for plasma protein binding decreased for
CL and T½ .  In contrast, Vdss predicted the observed value more accurately before
correcting for protein binding. Although the observed values represent data from only
one non-human primate, the parameters Cl, T½ and Vdss were all predicted within 38%.
Additional non-human primate studies may improve the accuracy of these results.
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Allometric scaling of blood clearance in mouse, rat, rabbit and non-human
primate was conducted to predict human clearance. Blood clearance of RP845 for each
animal model was plotted through allometric scaling pre (Figure 4.4) and post (Figure
4.5) correction for plasma protein binding.  Clearance increased slightly following
protein binding correction while the line fit remained similar.
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Figure 4.4 Allometric scaling of Blood Clearance for RP845-Tc-99m.
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Figure 4.5 Allometric scaling of Blood Clearance for RP845-Tc-99m corrected for
Plasma Protein Binding
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Half-life of RP845 for each animal model was plotted through allometric scaling
pre (Figure 4.6) and post (Figure 4.7) correction for plasma protein binding to predict for
human.  Half-life and line fit decreased following protein binding correction. Rat
appeared to have the largest impact on the fit of the line due to the highest protein
binding of the species.
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Figure 4.6 Allometric scaling of terminal half-life (t½) for RP845-Tc-99m.
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Figure 4.7 Allometric scaling of terminal half-life (t½) for RP845-Tc-99m corrected
for Plasma Protein Binding
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Vdss of RP845 for each animal model was plotted through allometric scaling pre
(Figure 4.8) and post (Figure 4.9) correction for plasma protein binding.  Vdss decreased
slightly following protein binding correction while the line fit correlation was excellent in
both cases.
Overall, predicted pharmacokinetic parameters in human following correction for
protein binding were 7.6 mL/min/kg, 70.6 minutes and 0.87 L/kg, for CL, t½ and Vdss
respectively.
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Figure 4.8 Allometric scaling of Volume of distribution (Vdss) for RP845-Tc-99m.
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Figure 4.9  Allometric scaling of Volume of distribution (Vdss) for RP845-Tc-99m
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4.5 Discussion
Allometric scaling of blood clearance and half-life for predicting non-human
primate values improved significantly following correction of protein binding. The line
correlation pre and post protein binding correction remained unchanged, however the
variation in protein binding between species was enough to improve the accuracy of the
predicted pharmacokinetic values once allometric scaling was adjusted.  Blood clearance
improved from 40% to 12% accuracy, which is significant, as clearance is important
when calculating administered dose and compound exposure in the blood. Vdss accuracy
did not improve when corrected for protein binding, however was still 38% accurate.
Line fit was > 0.97 pre and post correction for Vdss. It is also important to recognize that
data from only one non-human primate study was used and may have impacted the
predictive accuracy for estimating primate data from the three pre-clinical models and
also for predicting human results. Adding the one primate study into the analysis of
predicting the human pharmacokinetics and ultimately the dose, however should have
less impact on variability as the other models help define the extrapolated line estimate. It
is also interesting to note in this case that the predicted human pharmacokinetic
parameters were very close the non-human primate observed values, which was not
always the case in the programs reviewed in chapter three.
Blood clearance in all the models except mouse was faster than the glomerular
filtration rate (GFR) of each species, which indicates either kidney secretion or a
clearance route other than the kidney is occurring. In the case of the non-human primate,
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it is clear from the scintigraphic image that clearance is somewhat hepatobiliary. This
same pattern of hepatobiliary elimination may be expected in the human since the
predicted blood clearance rate is approximately three times faster than the GFR, which is
similar to the non-human primate.
Based on the qualitative image of plaque in the rabbit abdominal aorta (Figure
4.2), a 0.36 mCi*min/ml AUC blood exposure (Table 4.3) was sufficient to visualize the
plaque. Assuming the same blood exposure is needed in the human to provide a similar
qualitative image of plaque, a dose of 191 mCi/70kg subject would be required. This is
calculated by multiplying the predicted blood clearance in human (7.6 mL/min/kg) by the
AUC (0.36 mCi*min/ml), which gives a dose of 2.7 mCi/kg. A typical maximum dose
for a technetium-99m imaging agent is 0.36mCi/kg. A high dose of 2.7 mCi/kg would
potentially result in radiation toxicity to the kidneys or urinary bladder since this
compound is excreted renally. Even if the same exposure as achieved in the rabbit was
achieved in the human, it is unclear if the plaque could be visualized quantitatively using
technetium-99m and a scintillation gamma camera. This concern is based on the
resolution and sensitivity of scintigraphic imaging with RP845 Tc-99m, since in previous
studies it was insufficient to quantitatively assess plaque burden in the animal models. An
increase in plaque uptake or more sensitive imaging capabilities may be necessary for
RP845-Tc-99m imaging of atherosclerotic plaque.
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Based on the maximum human dose and blood clearance calculated through
allometric scaling corrected for protein binding, RP845 would be ineffective as a plaque-
imaging agent. Using the predicted pharmacokinetic information provides input into
structure-activity relationship (SAR), suggesting modifications that would help change
the disposition of the compound. For example, modifying the chemical composition of
the compound to decrease blood clearance may enhance uptake at the target. This chapter
presents a good example of how using allometric scaling corrected for plasma protein
binding to predict blood clearance of the compound in human helped evaluate the
compounds targeting potential and success of imaging atherosclerotic plaque.
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5. CHAPTER 5
Prediction of “First Dose in Human” for a Myocardial Perfusion Stress Agent Based
on Pharmacokinetics in Pre-Clinical Animal Models
5.1 Summary
DPC-A78445-00 is being developed as an alternative to exercise for increasing
blood flow in myocardial perfusion imaging for the evaluation of coronary artery disease.
DPC-A78445-00 is a C2 and 5' substituted adenosine analog with selective agonist
activity for the Adenosine 2a receptor.  Stimulation of this receptor mimics exercise
stress by directly inducing coronary vasodilation.  In vitro and in vivo pre-clinical studies,
including: blood stability, blood clearance, metabolic profiling, mass balance, plasma
protein binding and primary hepatocyte assays were conducted in mice, rats, dogs and
human models/biological matrices to understand the biological properties of DPC-
A78445-00 in each model for use in scaling dose to human.  In addition, dog
cardiovascular studies were conducted to examine the relationship between
pharmacokinetic and pharmacodynamic parameters to understand the pharmacokinetics
at the dose level required for appropriate coronary vasodilation.  Results indicated DPC-
A78445-00 was rapidly metabolized to the carboxylic acid by rodent blood in vitro
(t½ < 30 seconds) however, longer stability was observed in dog (t½ 41 minutes) and
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human blood (t½ 54 minutes).  These findings were confirmed in vivo, where plasma
levels of DPC-A78445-00 were virtually undetectable immediately after administration
in mice and rats, whereas, high levels of the carboxylic acid metabolite were
predominant.  In contrast, DPC-A78445-00 blood exposure, expressed as area under the
blood concentration-time curve (AUC) and blood clearance (CL), in the dog following a
1ug/kg dose were 34.1 ± 10.6 ng*min/mL and 31.6 ± 9.8 mL/min/kg, respectively. In
vitro primary hepatocyte assays indicated a similar rate of hydrolysis of the DPC-
A78445-01 ester to the carboxylic acid derivative in dog and human.   Mass Balance
recovery was greater than 90% as the carboxylic acid in rats and dogs with the major
excretory route for both species being hepatic.  Plasma protein binding of DPC-A78445-
00 was at a similar, moderate level in rat, dog and human plasma (80-93%). These
findings suggest the rat and mouse metabolize DPC-A78445-00 more rapidly than the
human and are, therefore, unlikely to be appropriate predictors.  In contrast, blood,
hepatocyte, and plasma protein binding for DPC A78445-00 was similar in the human
and dog and suggesting this species may be an appropriate predictor for the human.  This
finding was confirmed in a Phase I Human clinical trial that showed the AUC (23.1 ± 3.7
ng*min/mL) and clearance (44.1 ± 6.4 mL/min/kg) were similar in man to that found in
the dog.
In conclusion, a thorough in vitro and in vivo pharmacokinetic assessment of each
animal model including blood stability, hepatocyte assays, plasma protein binding and
blood pharmacokinetic analysis was necessary to select the appropriate species for
scaling to humans.  Dog was the only model similar to human with respect to disposition
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of DPC-A78445-00 and predicted human pharmcokinetic parameters (Cl, AUC) within
32% of observed values based on body weight.
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5.2 Introduction
Radionuclide myocardial perfusion imaging (MPI) is a widely used noninvasive
method for the evaluation of myocardial function or disease. MPI is typically done while
the heart is resting and under stress to create and detect any flow abnormalities. Exercise
stress is the preferred stress modality, however a significant number of patients are
unable to reach sufficient exercise levels to cause meaningful coronary vasodilation
because of physical conditions. Pharmacological stress agents can be divided into two
categories, coronary vasodilating agents (e.g. Dipyridamole and adenosine) and
catecholamines (e.g. Dobutamine), depending on their mechanism of action. Vasodilators
work directly on the coronary arteries to increase blood flow and catecholamines are
positive inotropic and chronotropic agents that increase cardiac workload and potentially
cause myocardial ischemia (Hendel et al., 2003). Pharmacologic stress using adenosine
or dipyridamole is increasingly being employed as an alternative to exercise stress with
myocardial perfusion imaging in patients suspected of having coronary artery disease.
Although the safety of these vasodilators has been well established, side effects occur
frequently and sometimes result in a suboptimal stress test or premature termination of
the study (Ranhosky et al., 1990; Cerqueira et al., 1994).  Whereas the desired coronary
vasodilatation during adenosine or dipyridamole infusion results from stimulation of the
A2A receptor subtype, the undesired side effects are due to stimulation of the other three
adenosine-receptor subtypes.  A selective adenosine 2a receptor (A2a), therefore, has the
potential to produce the required coronary vasodilation without the high incidence of
unwanted side effects.
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DPC A78445-00 was identified from a series of substituted adenosine analogs as
having high selectivity for the A2a receptor and sufficient duration of coronary
vasodilation following bolus administration in dogs to allow myocardial perfusion
imaging to be performed (Glover et al., 2001). DPC-A78445-00 is being developed as a
myocardial stress agent as an alternative to exercise in myocardial perfusion imaging for
the evaluation of coronary artery disease.
The FDA requires that the “first in human” dose be based on pre-clinical animal
model efficacy and safety testing to ensure a safe entry into Phase I clinical trials.
Interspecies scaling of pharmacokinetic parameters in the appropriate species is therefore
important for predicting drug doses in human clinical trials. The presence of a methyl
ester in the structure of DPC-A78445-00 (Figure 5.1) makes this agent potentially
susceptible to esterase activity and hydrolysis to the carboxylic acid, which may vary
between species.  It was therefore important to ensure that the fate of DPC-A78445-00 in
the species used in pharmacological models and toxicity studies predict for the human.
The stability of DPC-A78445-00 was examined in rat, mouse and dog blood and
compared with human blood.  It was also necessary to assess the extent of binding to
plasma proteins, which will affect free drug availability and altar clearance from the
blood.
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5.3 Materials and Methods
5.3.1 Chemistry
The structures of DPC-A78445-00 and JR3119 (Internal Standard) are shown in
Figure 5.1 and Figure 5.2, respectively. The internal standard is used to correct for losses
of the DPC-A78445-00 and the Carboxylic Acid Metabolite during sample handling.
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 Figure 5.1 Structure of DPC-A78445-00 and the Carboxylic Acid Metabolite
(ATL 146a)
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5.3.2 In vitro Blood stability
5.3.2.1 Sample Incubation
DPC-A78445-00 was incubated with fresh heparinized Sprague-Dawley rat,
mongrel dog, human (50 nM incubation concentration), and FVB mouse (35 nM
incubation concentration) blood at 37°C.  Aliquots (1 mL) were taken from rat and mouse
blood incubations at 0.5, 1, 2, 5, 15, 30, and 60 minutes and from the dog and human
samples at 1, 5, 10, 15, 30, and 60 minutes post-incubation (n=1/timepoint).  Blood was
transferred directly into 2 mL of acetonitrile containing 70 ng/mL JR3119 (Internal
Standard) and assayed immediately for DPC-A78445-00 and the carboxylic acid
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metabolite (ATL 146a).  An aliquot of control blood was prepared for each species to
assess background interference.  DPC-A78445-00 was incubated in saline over 2 h to
assess non-matrix stability.
5.3.2.2 Sample Extraction
Samples were vortexed for 30 seconds and centrifuged at 2000 x g for 15 minutes.
The supernatant was transferred to a fresh tube and centrifuged again to ensure removal
of precipitated protein.  The supernatant was transferred to a fresh tube where acetonitrile
was evaporated under a stream of nitrogen in a heating block at 37°C.  Samples were
reconstituted to a 1 mL volume with 9% acetonitrile / 0.1% formic acid.
5.3.2.3 DPC-A78445-00 Analysis
Extracted samples and standards (100 mL) were analyzed on a validated mass
spectrometry method (Gorman et al., 2003) using a Hewlett Packard 1100 multisolvent
HPLC delivery system (Hewlett Packard, Burlington, Massachusetts) and an
API 3000 MS/MS spectrophotometer (Applied Biosystems, Foster City, California).  The
analytical column was a Zorbax SB-CN (3.5 m particle, 4.6 x 150 mm) maintained at a
column temperature of 50°C and 1.0 mL flow rate.  Mobile phase A was 0.1% formic
acid (CH2O2), and mobile phase B was 0.1% CH2O2 containing 90% acetonitrile.  A
linear gradient from 10% to 60% mobile phase B over 22 minutes was used for the
elution of DPC-A78445-00 and its metabolite.  A six minute post-time of 10% mobile
phase B was used to equilibrate the column.  LC/MS/MS analysis was done in the
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electrospray positive ion, MRM scan mode for detection of DPC-A78445-00
(487.0/314.0 amu), JR3119 and ATL 146a (473.0/300.0 amu) m/z.  Nitrogen was used as
curtain, nebulizing and collision gas with settings of 12, 2 and 10, respectively.  Spray
voltage was set at 5500 volts and temperature at 450°C.  The retention times for
ATL 146a, JR3119 and DPC-A78445-00 were 10.0, 11.3 and 12.3 minutes, respectively.
A representative chromatogram is shown in Figure 5.3 illustrating resolution of peaks and
column retention times.  Standard curves for DPC-A78445-00 (0.119 - 91.6 ng/mL) and
ATL 146a (0.125 - 94.6 ng/mL) were prepared in 9% acetonitrile/0.1% formic acid.
JR3119 was also prepared in the same diluent at 70 ng/mL.  Standard curves and internal
standard recovery were used for the quantitation of DPC-A78445-00 and ATL 146a in
samples.  Analyte quantitation was determined using sample volume, peak area of
analytes and applying a correction factor based on internal standard recovery.
5.3.2.4 Data Analysis
Sample concentrations of DPC-A78445-00 and ATL 146a were determined by
comparison of internal standard (JR3119) adjusted peak area to standard curves for
DPC-A78445-00 and the carboxylic acid metabolite (ATL 146a).  The percent
conversion to the acid metabolite was calculated by dividing the total acid metabolite
(ng/mL) by the total acid metabolite and ester (ng/mL) quantitated in the sample.  Total
DPC-A78445-00 added to samples was recovered as either the ester or acid.  Half-life
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estimates were made by calculating the time for parent compound to decrease to 50% of
initial concentration.
Figure 5.3 Representative LC/MS/MS Chromatogram Illustrating Peak Resolution
and Column Retention Times of ATL 146a (RT=10.01), JR3119
(RT=11.33) and DPC-A78445-00 (RT=12.27)
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5.3.3 In vitro Hepatocyte Metabolism
5.3.3.1 Buffer Preparation
Krebs-Henseleit Buffer (KHB) with 2000 mg/L glucose was purchased from
Sigma (St Louis, Missouri) and supplemented with 0.373 g/L of calcium chloride and
2.1 g/L sodium bicarbonate.  KHB was adjusted to pH 7.4 (using 1N hydrochloric acid or
1N sodium hydroxide) and sterilized by vacuum filtration using a polyethersulfone (PES)
membrane with a porosity of 0.22 m.
5.3.3.2 Hepatocyte Preparation
Cryopreserved hepatocytes were purchased from In vitro Technologies, Inc.
(Baltimore, Maryland) and stored at -150°C prior to use.  Three lots of human
hepatocytes (#104, #129 and #CEK) from male and female donors ranging in age from
53 to 63 with varying medical history and one lot of hepatocytes each for dog (Male
Beagle, Lot #VWG) and rat (Male Sprague-Dawley, Lot #REM) were used.  On the day
of the study, hepatocytes were placed on ice for five minutes to release any liquid N2 then
placed into a 37°C water bath for 75-90 seconds to thaw.  The hepatocytes were
transferred into pre-warmed KHB and centrifuged for five minutes at 50 x g.  The
supernatant was discarded and the hepatocytes were resuspended in KHB at a
concentration of 1x106 cells/mL.
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5.3.3.3 Hepatocyte Incubation
Hepatocytes (1x106 cells/mL) were incubated for up to 2 h at 37°C/5% CO2 with
DPC-A78445-00 diluted in 0.9% saline.  Final incubation concentration of
DPC-A78445-00 was 50 nM.  Rat hepatocytes were sampled at five and 15 minutes post-
incubation, dog hepatocytes at 5, 15 and 120 min post-incubation, and human
hepatocytes at 1, 5, 15, 30, and 120 min post-incubation.  Samples (1 mL) were
transferred directly into acetonitrile (2 mL) and internal standard (JR3119, a methyl
ketone) was added.  Samples were vortexed for 30 seconds, centrifuged at 2000 x g for
15 minutes, supernatant decanted and centrifuged again to ensure removal of precipitated
protein.  The supernatant was transferred to a new tube and dried under a stream of
nitrogen in a heating block at 37°C to remove acetonitrile.  Extracts were re-constituted
in 9% acetonitrile/0.1% formic acid and assayed by LC/MS/MS (section 1.3.2.3).
Hepatocytes were incubated alone as controls in all studies for the determination of
matrix interference.
5.3.4 Data Analysis
Sample concentrations of DPC-A78445-00 and ATL 146a were determined by
comparison of internal standard (JR 3119) adjusted peak area to standard curves for
DPC-A78445-00 and the carboxylic acid metabolite (ATL 146a).  The percent
conversion to the acid metabolite was calculated by dividing the total acid metabolite
(ng/mL) by the total acid metabolite and ester (ng/mL) quantitated in the sample.
123
5.3.5 Pharmacokinetics
5.3.5.1 Animal Dosing
The Institutional Animal Care and Use Committee (IACUC) reviewed protocol
procedures and approved all experiments conducted with animals.
5.3.5.1.1 DPC-A78445-00 Clinical Formulation Test Article
Vials containing DPC-A78445-00 (BMS50685-8B; 25.0 mg/mL) in 8.8 mM
sodium citrate and 20 mg/mL sucrose buffer were prepared and stored as a frozen
solution. Vials without DPC-A78445-00 were also used as a formulation control diluent.
All vials were thawed at 22°C and appropriate volumes drawn for injection.
5.3.5.1.2 DPC-A78445-00 Safety Formulation Test Article
Vials containing DPC-A78445-00 (BMS50685-8B, 200 mg/mL) were prepared in 2%
DMSO/0.9% sodium chloride for injection. Vials without DPC-A78445-00 were also
used as a formulation control diluent.  Vials were brought to room temperature and
appropriate volumes drawn for injection.
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5.3.5.1.3 Rat
Female (~250 g) and male (~340 g) Sprague-Dawley rats were obtained from
Charles River Laboratories (Wilmington, Massachusetts).  After a 72 h-acclimation
period, DPC-A78445-00 clinical formulation was administered via the tail vein as a
150 mg/kg bolus dose in a volume of 6.5 mL/kg.
5.3.5.1.4 Dog
Female dogs (~14 kg) were acclimated in metabolism cages for 24 h prior to the
start of the study.  After the acclimation period, DPC-A78445-00 safety formulation was
administered via the cephalic vein as a 150 mg/kg bolus dose in a volume of 0.75 mL/kg.
Pharmacokinetic and pharmacodynamic parameters were also examined in
anesthetized, open-chest dogs.  Each dog received four intravenous doses (non-
cumulative) of DPC-A78445-00: 0.25, 0.5, 1.0, and 2.0 mg/kg, all in a volume of 2.0 mL.
Pharmacokinetic (PK) analysis included Cmax, area under the (time-plasma
concentration) curve (AUC), clearance (CL) and terminal (b-phase) half-life (t1/2).
Hemodynamic responses, expressed as percent change from baseline values, for each
dose level included heart rate, arterial blood pressure, left ventricular dP/dt, and coronary
blood flow. Coronary blood flow was measured by fixing a Doppler flow probe to the left
anterior descending coronary artery. Similar studies were also performed using the
carboxylic acid metabolite of DPC-A78445-00 (ATL 146a) to determine its potential role
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in hemodynamic responses.  Doses of 0.5, 2.0, 5.0, and 30.0 mg/kg of ATL 146a were
evaluated.
5.3.5.1.5 Mouse
Female FVB mice carrying the c-neu Oncogene (~25 g) from our in-house colony
were dosed intravenously with the DPC-A78445-00 clinical formulation via the tail vein
as a 150 mg/kg bolus dose in a volume of 6.5 mL/kg.
5.3.5.2 Sample Collection
5.3.5.2.1 Blood
Blood samples were collected into heparin treated syringes via terminal heart
puncture from individual rats and mice (n=1/time-point) at 1, 3, 5, 7, 10, 15, and 30
minutes post-injection and from the cephalic vein (opposite injection site) of the dog (n=8
time-points/dog, n=3) at 1, 3, 5, 7, 10, 15, 30, and 60 minutes post-injection.  Following
collection, blood (1 mL) was rapidly added to acetonitrile (2 mL) to denature any esterase
and precipitate proteins.
5.3.5.2.2 Urine and Feces
Animals (rats and dogs) were housed in metabolic cages, and samples remained at room
temperature (22°C) during the collection period.  Urine and feces were collected at
intervals of 0-24, 24-48 and 48-72 h post-injection for both rats and dogs.  Cage washes
were performed with 50% ethanol at the end of each collection interval for the dogs and
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at the end of the study for rats.  Cage wash recovery of DPC-A78445-00 was added to
urine recovery for the respective time interval.  All collection tubes were weighed pre-
and post-sample collection for use in recovery calculations.
5.3.6 Sample Preparation
Internal Standard (JR3119, a methyl ketone) was added to acetonitrile precipitated
blood and standards to correct for loss of compound during sample preparation.  Samples
were vortexed for 30 seconds and centrifuged at 2000 x g for 15 minutes.  The
supernatant was transferred to a polystyrene tube and centrifuged again to ensure removal
of precipitated protein.  Supernatant was collected and placed under a stream of nitrogen
in a heating block at 37°C to evaporate the acetonitrile.  All blood volumes were
determined prior to sample preparation and adjusted to original volume for analyte
quantitation.  Internal standard was used to correct for loss of compound during sample
preparation.  Urine and feces samples were extracted immediately following collection
intervals.  DPC-A78445-00 was extracted from urine following the same procedure used
for blood.  Acetonitrile (100-800 mL) was added to fecal collections depending on the
collection interval and the amount of fecal sample.  The first two collection intervals
received more acetonitrile to extract/dilute higher expected concentrations.
5.3.7 Data Analysis
LC/MS/MS analysis was conducted on all samples (section 1.3.2.3). Non-
compartmental blood pharmacokinetic analysis was performed using WinNonlinä
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Professional (Pharsight Corporation, Mountain View, California) software. Volume of
distribution at steady state (Vdss), Clearance of drug from the plasma (CL) and
Elimination half-life (t½) were calculated.
5.4 In vitro Plasma Protein Binding
5.4.1 Protein Binding Method
An in vitro ultrafiltration method for measurement of binding of drugs to plasma
protein was used in this study.  CentrifreeÒ ultrafiltration devices (Amicon, Beverly,
Massachusetts) use a molecular weight cutoff of 30,000 daltons to separate bound from
free drug.
5.4.2 Sample Preparation
Sprague-Dawley rat and mongrel dog plasma was obtained in house and human
plasma was purchased through a commercial vendor (Biological Specialty Corporation,
Colmar, Pennsylvania).  14C-DPC-A78445-00 was added to plasma, vortexed and
incubated at 37°C for 15 minutes on a rocker platform.  14C-DPC-A78445-00 was also
prepared in saline or deproteinized plasma to determine non-specific binding.
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5.4.3 Sample Analysis
Plasma, saline or deproteinized plasma (0.025 mL) aliquots (n=4) were
transferred to separate vials for pre-filtration counting using a Tri-carbÒ 2500TR liquid
scintillation counter (Perkin Elmer, Gaithersburg, Maryland).  A 0.3 mL aliquot of
plasma, saline or deproteinized plasma was transferred to a CentrifreeÒ micropartition
cartridge (n=4) and centrifuged at 2500 xg for 15 minutes at room temperature.  After
centrifugation, 0.025 mL aliquots (n=4) of filtrate were transferred to vials for liquid
scintillation counting.  All samples were counted in 7 mL vials containing 5 mL of
Ultima Gold scintillation fluid (Perkin Elmer, Gaithersburg, Maryland).
5.4.4 Data Analysis
The percent of DPC-A78445-00 bound to plasma proteins was calculated using
the following equation:
   DPC-A78445-00 Total  -  DPC-A78445-00 Unbound (filtrate)
% Bound = ------------------------------------------------------------------------------------------------ X 100
       DPC-A78445-00 Total
Where:
DPC-A78445-00 Total = Radioactivity (dpm) in 0.025 mL of sample before
ultrafiltration.
DPC-A78445-00 Unbound = Radioactivity (dpm) in 0.025 mL of filtrate.
(Data are reported as the mean ± standard error of the mean [SEM].)
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5.5 Results
5.5.1 In vitro Blood stability
5.5.2 Rat and Mouse
Incubation of DPC-A78445-00 with FVB mouse and Sprague-Dawley rat blood
resulted in almost immediate disappearance of the parent compound and accumulation of
the carboxylic acid metabolite.  At the first time point (0.5 min), more than 85% of the
starting DPC-A78445-00 had been depleted (Figure 5.4) in blood by both the rat and
mouse.  On the basis of the early time points, the t½ values for DPC-A78445-00 were
estimated (Table 5.1).  No matrix interference was observed in mouse or rat blood.
DPC-A78445-00 incubated in saline over 2 h showed no conversion to the acid
metabolite.
5.5.3 Dog and Human
Incubation of DPC-A78445-00 (50 nM) with mongrel dog and human blood
resulted in a slow decrease of DPC-A78445-00 (Figure 5.4).
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Figure 5.4 Stability of DPC-A78445-00 Over Time in Mouse, Rat, Dog, and Human
Blood Following Incubation at 50 nM
The decrease in parent compound was paralleled by an increase in the carboxylic
acid metabolite.  At the end of the incubation (60 min) the DPC-A78445-00
concentration in dog and human blood respectively was 16.3 nM (32.6% of initial ester
concentration) and 23.7 nM (47.4% of initial ester concentration).  Based on the
DPC-A78445-00 depletion curve, the t½’s for dog and human blood were calculated
(Table 5.1).  No matrix interference was observed for dog or human blood.
Table 5.1 Half-life of DPC-A78445-00 Incubated in Mouse, Rat, Dog, and Human
Whole Blood
Compound Mouse Rat Dog Human
A78445- t½ < 0.5 min < 0.5 min 41.4 min 54.3 min
DPC-A78445-00 was incubated with fresh heparinized blood from the FVB mouse (35 nM), Sprague-Dawley
rat (50 nM), mongrel dog (50 nM), and human (50 nM)
DPC-A78445-00 was rapidly (t½ <0.5 min) converted to the carboxylic acid
metabolite in rodent blood.  In contrast, the conversion was much slower (t½ > 40 min) in
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dog and human blood.  This finding suggests that esterase activity in rat and mouse blood
is either lower or absent in dog and human blood.  Differences in esterase activity
between species are well-established (Minagawa et al., 1995).  Furthermore, a
carboxylesterase has been identified that is released into the blood of rodents that is not
present in higher species (Buchwald, 2001).  The similar rate of conversion in dog and
human blood supports the dog being an appropriate model for vivo assessment of
DPC-A78445-00.
5.5.4 In vitro Hepatocyte Metabolism
Results indicate DPC-A78445-00 at 50 nM is rapidly metabolized by rat
hepatocytes with 97 ± 1.9% and 100 ± 0.4% converted to the acid metabolite (ATL 146a)
by five and 15 min, respectively.  In human and dog hepatocytes, DPC-A78445-00
conversion to ATL 146a was slightly less rapid with a 97 ± 1.4%and 100 ± 0.1%
conversion by 15 and 120 min, respectively, in human, and 73 ± 3.3% and 98 ± 1.6%
conversion by 15 and 120 min, respectively, in dog.  The percentage of DPC-A78445-00
converted to the acid metabolite at respective time points is shown in Table 5.2.
Hepatocyte metabolism in human, dog and rat following incubation of DPC-A78445-00
(50 nM) is depicted in Figure 5.5.  Comparison of three different lots of human
hepatocytes showed similar conversion to the acid metabolite at 15 minutes (94.8%,
99.5% and 96.5%) and 120 minutes (99.7%, 100% and 99.6%).  The total amount of
132
DPC-A78445-00 added to incubations was accounted for as DPC-A78445-00 or acid
metabolite in samples analyzed.
Table 5.2 Hepatocyte Metabolism of DPC-A78445-00 Incubated at 50 nM in Rat,
Dog and Human Hepatocytes.  Percent Converted to the Acid Metabolite
(± SEM)
Incubation Time (min) Human Dog Rat
1 31.2 - -
5 65.6 48.0 ± 3.9 97.0 ± 1.9
10 87.7 - -
15 94.8, 99.5, 96.5a 73.0 ± 3.3 100.0 ± 0.4
30 99.3 - -
120 99.7, 100, 99.6a 98.0 ± 1.6 -
a3 separate lots of human hepatocytes
Human 15 and 120 min, Dog 5 min, Rat 5 min: n=3 replicates/same lot
Dog 15 and 120 min, Rat 5 min: n=4 replicates/same lot
Human 1, 5, 10, and 30 min: n=1 replicate/same lot
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Figure 5.5 Hepatocyte Metabolism of DPC-A78445-00 in Rat, Dog and Human.
Loss of Parent Compound and Formation of Metabolite
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Rat hepatocytes converted DPC-A78445-00 to the carboxylic acid metabolite
almost immediately (97% converted by five minutes).  Rapid conversion is also seen with
both dog and human hepatocytes.  These data are consistent with high levels of esterase
activity being present in the liver (Satoh T, et al., 1995).  The rapid conversion of
DPC-A78445-00 by both human and dog hepatocytes supports the dog being appropriate
for in vivo assessment of DPC-A78445-00.  These results indicate that human, dog and
rat hepatocytes handle DPC-A78445-00 in a similar manner and result in rapid hydrolysis
to the carboxylic acid metabolite.  The rapid conversion of DPC-A78445-00 by both
human and dog hepatocytes also supports the dog being appropriate for vivo assessment
of DPC-A78445-00.
5.5.5 Plasma Protein binding
Plasma protein binding results were similar between species at 50-200 nM with
91.0 ± 0.1%, 85.3 ± 0.4% and 92.6 ± 0.2% protein bound for rat, dog and human,
respectively.  Protein binding for the 500 nM incubation in dog and human plasma was
79.4 ± 0.4% and 89.8 ± 0.1%, respectively.  Non-specific binding at 500 nM in saline and
deproteinized human plasma was 22.7 ± 2.0% and 24.9 ± 1.4%, respectively (Table 5.3).
Non-specific binding was similar at 50 nM.
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Table 5.3 Percent of 14C-DPC-A78445-00 Bound to Plasma Proteins In vitro at
15 Minutes of Incubation in Human, Dog and Rat
Species
DPC-A78445-00 Human Dog Rat
Concentration (nM) Mean SEM Mean SEM Mean SEM
50 92.6 0.2 85.3 0.4 a91.0 0.1
500 89.8 0.1 79.4 0.4 - -
aIncubation at 200 nM
Values not adjusted for non-specific binding (Saline=22.7 ± 2.0, Deproteinized human plasma=24.9 ± 1.4)
All samples were incubated for 15 minutes.
SEM=Standard Error of the Mean for three replicate filtrates counted three times each.
Protein binding is moderate in plasma from all species tested.  The small
difference in protein binding between species may be attributed to the different binding
properties of the type and quantity of proteins unique to each species.  Similar levels of
binding were seen in human and dog plasma at either 50 or 500 nM.  These data suggest
that similar in vivo protein binding would be expected between human and dog with the
same free drug available to target the A2a receptor. In conclusion, plasma protein binding
of  DPC-A78445-00 is similar for the rat, dog and human.
5.5.6 Pharmacokinetics
5.5.6.1 Blood Pharmacokinetics
The blood concentration -time profiles following a single I.V. dose of 150 mg/kg
DPC-A78445-00 in the mouse, rat and dog are depicted in Figure 5.6 and Figure 5.7.
Blood levels of DPC-A78445-00 were low (< 0.1 ng/mL by five minutes) and the
carboxylic acid metabolite levels were high in rats (female and male) and mice at early
time points.  This almost immediate conversion prevented pharmacokinetic parameter
analysis for DPC-A78445-00 in the rat or mouse.  The carboxylic acid metabolite in the
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rat (male and female) and mouse (female) had similar Cmax, terminal half-life and AUC
(Table 5.4).
Blood levels of DPC-A78445-00 in the dogs were higher than the carboxylic acid
at early time points (one and three minutes) but declined to below metabolite levels after
five minutes (Figure 5.7).  The Cmax, terminal half-life (t½), systemic clearance (CL),
area under the curve (AUC0-8 ), and volume of distribution at steady state (Vdss) of
DPC-A78445-00 in the dog was 746 ng/mL, 9.0 min, 93.9 mL/min/kg, 1561 ng*min/mL,
and 0.24 L/kg, respectively (Table 5.5).  The carboxylic acid metabolite had a Cmax,
terminal half-life and AUC of 55 ng/mL, 19.8 min and 1303 ng*min/mL, respectively
(Table 5.4).
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 Figure 5.6 Blood Levels of DPC-A78445-00 and the Carboxylic Acid (ATL 146a)
Metabolite in the Rat or Mouse Following an I.V. Bolus Dose of
150 mg/kg
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Figure 5.7 Blood Levels of DPC-A78445-00 and the Carboxylic Acid (ATL 146a)
Metabolite in Dog Following an I.V. Bolus Dose of 150 mg/kg
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Table 5.4 Blood Pharmacokinetics of ATL 146a  Carboxylic Metabolite Following
an I.V. Dose of 150 mg/kg DPC-A78445-00 in Dogs, Rats and Mice
Species / #Animals Cmax
(ng/mL)
AUC (0-¥)
(ng? min/mL)
T½ (terminal)
(min)
Dog (female) / n=3 54.7 ± 27.7 1303 ± 595 19.8 ± 2.0
Rat (female) / n=1/Time-point 579 2315 7.5
Rat (male) / n=1/Time-point 386 2039 8.7
Mouse (female) / n=1/Time-point 494 2177 8.1
Mean ± SD
Table 5.5 Blood Pharmacokinetics of DPC-A78445-00 Following an I.V. Dose of
150 mg/kg in Dogs (n=3)
Dose
(mg/kg)
Cmax
(ng/m)L
AUC (0-¥)
(ng? min/mlL
T½
(terminal)
(min)
CL
(mL/min/kg)
Vdss
(L/kg)
150 746 ± 157 1561 ± 339 9.0 ± 2.0 93.9 ± 22.6 0.24 ± 0.04
Mean ± SD
5.5.7 Dog pharmacokinetics/pharmacodynamics
Measurement of blood levels of DPC-A78445-00 showed a dose-related increase
in Cmax and AUC (Table 5.6).  After administration of the target dose of 1.0 mg/kg,
clearance averaged 31.6 ± 9.8 mL/min/kg and the terminal half-life was 7.5.± 2.9
minutes.  Nearly identical values for these two parameters were observed with the highest
dose (2.0 mg/kg), as well.  The blood clearance rate of DPC-A78445-00 following I.V
administration of the same test article is close to the literature value for hepatic blood
flow in the dog (30.9 mL/min/kg) suggesting hepato-biliary clearance (Davies et al.,
1993). Bolus intravenous administration of DPC-A78445-00 to dogs produced a dose-
related increase in both magnitude and duration of coronary blood flow from 0.25 to 2
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mg/kg, which correlates well with the pharmacokinetic data (Figure 5.5). Coronary blood
flow was measured by fixing a Doppler flow probe to the left anterior descending
coronary artery. The dose to produce the required clinical response is 1 mg/kg based on
coronary blood flow. This dose was selected based on achieving a sufficient elevation in
blood flow over a 6-8 minute duration and acceptable drop in peripheral blood pressure.
The pharmacokinetic parameters for DPC-A78445-00 in the dog indicated a dose of
150 mg/kg produced a very high circulating level that was very rapidly cleared.  However,
when compared to lower doses, the pharmacokinetic data were not linear. The Cmax and
AUC were slightly lower than would have been predicted for the 150 mg/kg dose.  In the
current study the clearance rate was greater than resting hepatic blood flow in the dog
(30.9 mL/min/kg) and the steady state volume of distribution was high.  The changes in
these parameters at this dose level may be the consequence of DPC-A78445-00 influencing
peripheral vasodilation and changing hepatic blood flow (Sakata et al, 1999).
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 Figure 5.8 DPC-A78445-00 Blood Levels Following I. V. Bolus Administration
5.5.8 PK Analysis of the carboxylic acid metabolite after administration of
DPC-A78445-00
Measurement of plasma levels of ATL 146a following the administration of
DPC-A78445-00 to anesthetized dogs showed a dose-related increase for both Cmax and
AUC (Table 5.7). After administration of the pharmacologically active dose of 1.0 mg/kg
of DPC-A78445-00, the Cmax of ATL 146a was only 0.8 ng/mL - one-fourth the plasma
concentration observed when 0.5 mg/kg of the carboxylic acid metabolite itself was
administered to a separate group of dogs (Table 5.8). The terminal half-life of the
carboxylic acid metabolite averaged 18.3 min, 2.4-fold longer than the half-life observed
for DPC-A78445-00.
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5.5.9 PK Analysis of the carboxylic acid metabolite (ALT 146a) after
administration of this metabolite
Table 5.8 shows the blood pharmacokinetic data from a set of experiments in
which the metabolite was administered to anesthetized dogs as an IV bolus at doses
ranging from 0.5 to 30 mg/kg.  These studies were performed to more completely
understand the pharmacodynamic and pharmacokinetic behavior of the carboxylic acid
metabolite.  Administration of 0.5 mg/kg of ATL 146a produced a Cmax of 3.3 ng/ml, a
value that was approximately twice that observed after administration of 2 mg/kg of
DPC-A78445-00 (1.6 ng/mL).  The clearance rate of ATL 146a ranged between 20 and
25 mL/min/kg with the four doses evaluated, averaging 22.1 mL/min/kg. This value is
approximately 30% slower than the clearance of DPC-A78445-00, consistent with a
longer (@ 2.6-fold) elimination half-life for the carboxylic acid metabolite.
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Table 5.6 Blood Pharmacokinetics of DPC-A78445-01 Following I.V.
Administration of DPC-A78445-00 in Dogs (n=4)
Dose
(mg/kg)
Cmax
(ng/ml)
AUC (0-inf)
(ng.min/mL)
T1/2 (terminal)
(min)
CL
(ml/min/kg)
Vdss
(L/kg)
0.25 2.6 ± 0.8 7.7  ± 3.2 2.8 ± 0.8 35.8 ± 11.8 0.11 ± 0.04
0.5 4.5 ± 1.6 12.0  ± 3.6 3.9  ± 2.0 45.1  ± 13.2 0.17  ± 0.05
1 12.1 ± 2.4 34.1 ± 10.6 7.5 ± 2.9 31.6  ± 9.8 0.15 ± 0.03
2 29.8  ± 2.2 65.3 ± 15.2 7.3 ± 0.8 31.7 ± 6.3 0.12  ± 0.01
Table 5.7 Pharmacokinetic Parameters of ATL 146a (Acid Metabolite) in Dogs
(n=4) Following I.V. Administration of DPC-A78445-00
Dose
(mg/kg)
Cmax
(ng/mL)
AUC (0-inf)
(ng.min/mL)
T1/2 (terminal)
(min)
0.5 0.6  ± 0.27 11.2 ± 6.7 10.7 ±  2.2
1 0.8  ± 0.26 28.9  ± 12.5 22.8  ± 6.5
2 1.6 ± 0.15 51.2  ± 6.11 22.7  ± 3.6
Table 5.8 Pharmacokinetic Parameters of ATL 146a (acid metabolite) in Dogs (n=6)
Following  I.V.  Administration of ATL 146a
Dose
(mg/kg)
Cmax
(ng/mL)
AUC (0-inf)
(ng.min/mL)
T1/2 (terminal)
(min)
CL
(ml/min/kg)
Vdss
(L/kg)
0.5 3.3 ± 2.2 26.0 ± 11.3 20.3 ± 11.5 21.5 ±  6.8 0.41 ± .02
2 15.2 ± 8.1 104.1 ± 35.9 19.6 ±  6.7 20.8 ± 5.8 0.42 ±  0.19
5 38.0 ± 14.0 257.5 ± 56.2 19.2 ± 3.5 20.2 ± 4.1 0.43 ± 0.11
30 233.7 ± 123.1 1232.6 ± 295.6 14.2 ± 7.6 25.7 ± 7.3 0.43 ± 0.34
Concentration of DPC-A78445-00 in blood correlates with increase in coronary
blood flow with increasing doses (Figure 5.5).
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Figure 5.5 DPC-A78445-00 Effect on Coronary Blood Flow and Blood Levels
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5.5.9.1 Mass Balance
      Total recovery of DPC-A78445-00 and the carboxylic acid metabolite in mass balance
studies in rats was almost complete by 72 h with the majority cleared in the feces for both
male and female (Table 5.9).  The majority (> 80%) of the dose was excreted as the
carboxylic acid metabolite within the first 24 h  (Table 5.9).  Total recovery of DPC-
A78445-00 and the carboxylic acid metabolite in the mass balance studies in dogs was also
almost complete by 72 h with the feces being the major route of excretion (Table 5.10).  The
majority (> 83%) of DPC-A78445-00 was excreted in dogs over the first 48 h as the
carboxylic acid metabolite. Results from the study conducted with primary hepatocytes
described previously indicated rapid metabolism of DPC-A78445-00 to the carboxylic acid
metabolite (ATL 146a), which explains why this metabolite was the only form of
DPC-A78445-00 found in fecal excretion.  Comparison of male and female rats did not
indicate a major difference in mass balance results.  The experimental group sizes were very
small, therefore statistical comparison was not performed.
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Table 5.9 Percent Recovery of an Intravenous Dose of DPC-A78445-00 in Excreta
Collected from Female and Male Rats (n=4/sex)
Collection Interval, h % Urine SEM (+/-) % Feces SEM (+/-) % Recovery SEM (+/-)
Female
0-24 3.7 0.79 79.3 3.35 83.0 3.84
24-48 0.1 0.03 11.1 3.00 11.1 3.01
48-72 0.4 0.15 0.3 0.12 0.7 0.26
Total % Recovery 4.1 0.81 90.6 2.56 94.8 2.34
Male
0-24 10.1 1.03 79.3 6.66 89.3 5.73
24-48 0.2 0.05 7.3 2.82 7.6 2.82
48-72 0.4 0.06 0.2 0.06 0.6 0.11
Total % Recovery 10.7 1.11 86.7 3.97 97.4 3.06
147
Table 5.10 Percent Recovery of an Intravenous Dose of DPC-A78445-00 in Excreta
Collected from Female Dogs (n=3)
Collection Interval,h Urine SEM (+/-) Feces SEM (+/-) % Recovery SEM (+/-)
0-24 8.2 1.58 21.4 21.38 29.6 21.60
24-48 5.1 4.88 48.7 24.47 53.8 19.67
48-72 3.3 2.76 3.3 2.75 6.6 5.51
Total % Recovery 16.7 3.63 73.3 4.53 90.0 1.04
5.5.9.2 Metabolism
DPC-A78445-00 was almost immediately converted to the carboxylic acid
metabolite in the blood of rats and mice. In contrast, blood levels of DPC-A78445-00 in
the dogs were higher than the carboxylic acid at early time points (one and three minutes)
but declined to below metabolite levels after five minutes. Figure 5.9 and Figure 5.10
show representative LC/MS/MS chromatograms in rat and dog blood, respectively. Both
species showed only carboxylic acid metabolite (ALT 146a) and no DPC-A78445-00 in
the urine and fecal samples at all collection times.  The recovery in mass balance studies
indicated the carboxylic acid metabolite could account for > 90% of the administered
DPC-A78445-00 dose in both rats and dogs.  This indicates the carboxylic acid
metabolite is the only major metabolite.
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Figure 5.9  Representative LC/MS/MS Chromatogram of DPC-A78445-00 Extracted
From Rat Blood 1 min Post-injection (ATL 146a Acid Metabolite=RT 9.9
min, JR3119 Internal Std=RT 11.2 min, DPC-A78445-00=RT 12.1 min)
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     Figure 5.10  Representative LC/MS/MS Chromatogram of DPC-A78445-00 Extracted
From Dog Blood 30 min Post-injection (ATL 146a Acid Metabolite=RT
9.8 min, JR3119 Internal Std=RT 11.1 min, DPC-A78445-00=RT
12.1 min)
DPC-A78445-00 was non-detectable in rat and mouse blood samples by five minutes post-
dose, which is consistent with hydrolysis occurring in the blood.  In contrast, blood samples
from the dog indicated high circulating levels of parent compound at early time points with
limited levels of the carboxylic acid metabolite (ATL 146a).  These findings are consistent
with the findings of the current work for stability of DPC-A78445-00 when incubated with
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rodent or dog blood in vitro.  The rapid conversion of DPC-A78445-00 to the carboxylic
acid metabolite (ATL 146a) seen in mice and rats compared to slower conversion in dogs
may be explained by the higher esterase activity (100-400x) reported for rat whole blood, as
compared to dog and human blood (Minagawa et al, 1995).
In conclusion, following I.V. administration, DPC-A78445-00 is converted in the
blood of rats and mice very rapidly to the carboxylic acid metabolite resulting in minimal
systemic exposure to the parent compound.  Administration of DPC-A78445-00 to dogs
results in high circulating levels of parent compound at early time points.  While both
DPC-A78445-00 and the carboxylic acid metabolite are rapidly cleared, a slightly longer
half-life for the metabolite results in the metabolite levels exceeding the parent compound
after five minutes post-dose.  Elimination of DPC-A78445-00 in both rats and dogs is
predominantly in the feces as the carboxylic acid metabolite.
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5.6 Discussion
This chapter emphasizes the importance of understanding the disposition of a
compound in each species prior to using it for allometric scaling predictions. The
presence of a methyl ester in DPC A78445-00 presented a potential for rapid hydrolysis
to the carboxylic acid. The short duration of pharmacological activity in the dog model
suggested rapid clearance and made it critical to understand the handling of DPC
A78445-00 in the dog and ensure it represented the human.  The handling of
DPC-A78445-00 was therefore examined in rat and dog blood, whole animal studies of
metabolism, pharmacokinetics, elimination and primary hepatocyte metabolism. These
results were compared with human blood stability and human hepatocyte metabolism.
From these studies, it was recognized the dog and human handle DPC A78445-00 in a
similar manner. In contrast, rats hydrolyze DPC-A78445-00 to its carboxylic acid
metabolite very rapidly in whole blood. The similar profile of DPC-A78445-00 in dog
blood and dog hepatocytes to human blood and human hepatocytes supports the dog
being an appropriate testing species.  Pharmacokinetic and mass balance studies in the
dog indicated hepatic clearance at a rate equivalent to hepatic blood flow.  This data
indicates that human clearance of DPC-A78445-00 will be hepatic and at a rate
approximating human hepatic blood flow.
Based on the pharmacology studies in the dog model, a bolus dose of 1ug/kg DPC
A78445-00 was identified as producing a sufficient increase in coronary blood flow to
allow stenosis imaging with a perfusion tracer.  The selected dose of 1 ug/kg for human
clinical trials was the optimal dose that elicited an acceptable increase in heart rate with
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fewer adverse events than the commercially available vasodilator, adenosine™ (Hendel
et al., 2005). The blood exposure, or area under the curve, for a 1ug/kg dose of DPC-
a78445-00 in dogs was 34.1± 10.6 ng*min/mL.  In contrast, the exposure in human for
the same dose was 23.1± 3.7. The large standard deviation in the dog may indicate an
overestimate of the difference in results. A comparison of dose at 0.25 ug/kg in the dog to
0.3 ug/kg in human, indicates an AUC of 7.7±3.2 and 6.3±1.8 ng*min/mL, respectively.
The percent difference between dog and human at both dose levels is <32%. The
prediction of a 1 ug/kg dose for humans, made prior to the start of clinical trials based on
body weight using pharmacokinetic data from only the dog, proved to be an extremely
accurate prediction. This project emphasizes the need to fully characterize all pre-clinical
animal models with respect to pharmacokinetics to ensure using the correct model data
for prediction of human dose.
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6. CHAPTER 6
6.1 General Conclusions and Future Research
6.1.1 Summary and conclusions
The overall goal of this research was to examine the feasibility of using weight
based allometric scaling as a predictive tool to estimate human pharmacokinetic
parameters from pre-clinical animal data.  Data for three imaging agents and a
pharmacological stress agents (Oncology tumor agent (DPC-A80351), Thrombus agent
(DMP-444), Infection agent (RP-517) Pharmacological stress agent (DPC-A78445-00))
that entered human clinical trials, and an imaging agent being developed (RP845) were
assessed for scaling accuracy.  Initially pharmacokinetic data from animal models were
used to extrapolate to human though body weight allometric scaling.  Subsequently the
impact of adjusting for plasma protein binding and the impact of metabolic stability in the
different models was examined.
Allometric scaling of animal pharmacokinetic parameters (clearance, half-life and
volume of distribution) achieved a prediction of the human pharmacokinetic parameter
with an accuracy of 13 to 109% for the three imaging agents with available clinical data.
This prediction was further improved by adjusting for plasma protein binding of the drug
and achieved an accuracy of 5 to 57% of the clinically observed values. This level of
predictivity closely approached the thesis target of achieving a mathematical model that
would allow prediction of human dose within 30%.  In fact, if clearance was taken as the
primary pharmacokinetic value, the weight based allometric scaling with protein binding
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adjustment was predictive within 12.5 % based on a retrospective analysis.  Recent work
by Tang and co-workers (2005), reported predicting human clearance values within 78%
with a new method using rat and human data only. They also compared their accuracy
with simple allometric scaling (323%) and the rule of exponents (185%).  A 12.5%
prediction accuracy is excellent considering recently published literature and would
provide clinical dose estimates within a much smaller range.
Weight based allometric scaling was further examined for an atherosclerotic
plaque targeted radiopharmaceutical imaging agent, RP845-Tc-99m, currently in
development. Pharmacokinetic parameters were determined in mouse, rat and rabbit,
allometric scaling was used to predict the non-human primate value.  Differences
between predicted versus observed non-human primate Cl, t½ and Vdss, were 40%, 52%
and 8%, respectively.  Correcting for plasma protein binding improved the prediction for
Cl and t½ to within 12 and 3 %, respectively. Vdss prediction, however, became less
accurate (38% difference).  Since blood clearance is the major parameter in predicting
human dose, the improvement from 40% to 12% accuracy is important.  The plasma
protein binding adjusted animal data were then used with allometric scaling to predict
human CL, t½ and Vdss.  Results were 7.6 mL/min/kg, 70.6 minutes and 0.87 L/kg,
respectively. Based on the predicted human blood clearance and the dose required to
image atherosclerosis in a rabbit model, the human dose would be unacceptably high.
This demonstrates how allometric scaling can be used in research projects to assess
clinical feasibility.
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The impact of metabolic differences influencing the reliability of using different
species to predict for man was highlighted by DPC-A78445-00. This agent is being
developed as an alternative to exercise in myocardial perfusion imaging for the
evaluation of coronary artery disease. DPC-A78445-00 was rapidly metabolized to the
carboxylic acid by mouse and rat blood in vitro and in vivo, however, longer stability was
observed in the dog. Human blood in vitro data were consistent with the dog data
suggesting the mouse and rat would not be representative. DPC-A78445-00 plasma
protein binding was at a similar, moderate level in rat, dog and human plasma, and
metabolism by hepatocytes was rapid for all three species. Lave and co-workers, 1997,
also found that using in vitro metabolism data (i.e. hepatocytes) to adjust allometric
scaling dramatically improved the prediction of human clearance (80% to 40%)
compared to the approach in which clearance is directly extrapolated using body weight.
Phase I human clinical trial testing determined the area under the blood concentration-
time curve (AUC) and clearance predicted by the dog were within 32% of the human
values.
The research presented in this dissertation has identified that weight based
allometric scaling of clearance from appropriate pre-clinical animal models can clearly be
useful in predicting the human dose levels of imaging agents for Phase I clinical testing.
It has also identified that allometric scaling of clearance from animal models when
corrected for plasma protein binding yielded reliable predictions of the human clearance
(differed by < 30%) for radiopharmaceutical imaging agents.  Furthermore, the
application of scaling models provided insight into the translation from pre-clinical
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testing to human application and assessment of feasibility.  The need to assess and select
appropriate animal models that will represent the human was highlighted in the final
chapter and emphasizes difficulty in trying to achieve models that will be robust and
reliable across all situations.
Considering the following statements from colleagues in the field of
pharmacokinetics, this research has proven consistent with their sentiments and extended
the application of one approach into the radiopharmaceutical field.
“Although allometric scaling has much utility as a retrospective tool, like any
other method its prospective applicability is not optimal” (Bonate et al, 2000).  Nagilla
and co-workers, 2005, believe that no single method identified to date offers the “perfect”
solution, and welcomes ongoing efforts by the scientific community to continue to refine
the peer-reviewed knowledge in this field.
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6.1.2 Future Research
Future research in the area of predicting pharmacokinetics could include;
· Following the fate of the parent and metabolites over the entire blood concentration-
time curve. This would provide a total “mass balance” of all forms of the drug within
the blood circulation for determining full kinetic information related to protein
binding, clearance rates and clearance routes of parent drug/metabolites.
· Investigating the accuracy of predicting toxicokinetics that are conducted with high
doses of a test agent from pre-clinical studies typically done with low doses. Basically
determining predictability through a range of doses and how saturating enzymes,
receptors and clearance mechanisms may affect disposition of the drug.
· Determining a method to evaluate how to predict from animal models into a human
with a known disease state. This may involve testing pre-clinical models with the
disease or trying to model known variations caused by the human disease state and
applying them to normal animal data.
· Investigating drug-drug interactions with respect to competing for protein binding,
receptor binding or clearance mechanisms that may vary between species and affect
predictive success.
These additional areas of investigation would provide significant information on the
utility and capability of predicting human pharmacokinetics.
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